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1 General introduction 
1.1 Alzheimer’s disease 
 
Alzheimer's disease is one of the most common causes of dementia, accounting for 
approximately 60-80% of all cases, with no effective treatment or definitive ante-mortem 
diagnostic test (1,2). Increasing life expectancy along with the exponential rise of 
incidence of AD, position the disease as one of the main challenges to society and the 
health care system at present (1-3). The disease is characterised by abnormalities 
including a disruption of neuronal function, progressive memory loss, and a gradual 
cognitive, functional and behavioural deterioration (4). Despite noteworthy progress in 
unravelling the biological foundations of AD, the etiological mechanisms underlying the 
neuropathological changes in AD remain unclear. They probably involve environmental, 
epigenetic as well as genetic factors (5).  
 
AD was named almost 100 years ago after a German physician, Alois Alzheimer (1864-
1915) (6). According to Alzheimer’s original case report, published in 1907, the disease 
was characterised by the presence of miliary foci and neurofibrils in the post-mortem 
cerebral cortex region of a patient called “Auguste D”, who had shown progressive 
cognitive impairment, focal symptoms, hallucinations, delusions, and psychosocial 
incompetence (6). In this landmark paper, he remarkably identified the two hallmarks of 
AD that are known to be common to all forms of AD (7). These hallmarks are 
extracellular senile plaque deposition, which is mainly composed of Aβ peptide, and 
intracellular neurofibrillary tangle formation, which is composed of hyperphosphorylated 
forms of the microtubule associated protein tau (8). Presently, the disease is characterized 
by presence of these two hallmarks as well as vascular pathology (e.g. cerebral amyloid 
angiopathy) and brain atrophy (Fig. 1.1). These pathologies are often accompanied by 
gliosis, loss of white matter and synapses. Other features of AD pathologies include 
Lewy bodies, actin-immunoreactive Hirano bodies and inflammatory processes, e.g. 
oxidative stress and mitochondrial dysfunction (9). Furthermore, failure of 




Fig. 1.1. The pathological hallmarks of AD. (A) Photomicrograph shows an Aβ plaque (upper arrow) 
and a neurofibrillary tangle (lower arrow) in an 85-year-old individual with autopsy-verified AD. (B) 
Cerebral amyloid angiopathy is commonly observed in mouse models of AD and AD patients. Aβ40 is 
deposited around cerebral vessels. (C) Atrophy and clinical stage of AD: mild cognitive impairment 
(MCI) and AD patients showed atrophy compared to normal patients Figs 1.1 A and C are 
reproduced, with permission, from Jack, 2012 (10). ©rsna.org. 
 
have also been reported (8,11). Since learning and memory are thought to be associated 
with synaptic efficacy, such as long-term potentiation and long-term depression, synaptic 
alterations and loss are considered by some investigators to be the major neurobiological 
cause of cognitive dysfunction in AD (12-14).  
 
While the etiology of the disease has been the subject of considerable debate, the amyloid 
cascade hypothesis suggests that altered cleavage of amyloid precursor protein, which 
leads to accumulation of different forms of Aβ peptide in the brain, is central to the 
pathological cascade that leads AD development (15). This hypothesis was initiated after 
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isolation of Aβ from cerebrovascular fibrils (16-18). Aβ40 and Aβ42 peptides, which are 
the major constituents of the Aβ plaques, are derived from an integral type 1 trans-
membrane integral protein through sequential cleavage by β-secretase and γ-
secretase/presenilin complexes (19,20). These peptides can be either diffuse or compact 
in nature (17). Aβ peptides have the ability to self-aggregate and form large amyloid 
fibrils (21). Although both soluble oligomer forms of Aβ and insoluble forms, i.e. 
amyloid fibrils, have been associated with toxicity (22-24), recent studies have suggested 
that the soluble oligomer forms of Aβ are the most neurotoxic species (25), and have 
been associated with AD pathogenesis (26,27). How insoluble Aβ causes neurotoxicity is 
still not fully understood. Interestingly, the presence of insoluble Aβ does not correlate 
well with cognitive decline in AD (28,29), although some degree of correlation has been 
shown between Aβ load and cognitive decline (30). The main evidence supporting the 
amyloid cascade hypothesis has come from identification of mutations in the APP gene 
(31), which are linked to the early onset of autosomal-dominant familial type of AD 
(mean age at onset <65 years old). Additional support for this hypothesis comes from the 
identification of the APP gene’s location on chromosome 21. Adults with Down’s 
syndrome (trisomy 21), who have an extra chromosome 21, frequently (60%) develop 
AD in the sixth decade of life. This is thought to be due to excess production of the APP 
as a consequence of the trisomy, which leads to formation of amyloid plaques, neuronal 
cell dead and clinical AD (32).  
 
Under normal physiological conditions, cleavage of APP by α-secretase precludes Aβ 
formation, whereas all FAD mutations near the β- or γ-secretase cleavage site of APP 
lead to an increase in the forms of Aβ that can aggregate. The amyloid cascade 
hypothesis was further supported by identification of mutations in PS1 (33) and PS2 (34), 
which are proteins that form the catalytic active site of the γ-secretase complex. The 
mutated form of these proteins can lead to production of more Aβ42, which leads to an 
increase in Aβ42/Aβ40 ratio (35,36).  
 
Even though mutated genes in FAD are well characterized, the mutations in genes 
contributing to the disease formation in the LOAD are still under investigation. A few 
loci, such as the apolipoprotein E, have been derived from genome-wide association 
studies and have been linked with late onset AD (37,38). These AD gene candidates have 
been categorized into four groups, namely Aβ metabolism, lipid metabolism, innate 
immunity, and cell signalling (39) suggesting that multiple factors might be involved in 
the progression of AD. Clearly, there is an urgent need to have complete appreciation of 
Chapter 1 
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the full scope of AD pathology. To this end, it is essential to understand 
neuropathological factors that contribute to AD pathology. For example, cerebrovascular 
abnormalities leading to blood flow disturbances and white matter abnormalities, such as 
demyelination, are considered to be important risk factors for AD. However, how these 
abnormalities contribute to the disease progression remains unclear. 
1.1.1 Cerebrovascular abnormalities and blood flow disturbances  
Accumulating evidence suggests that AD is associated with cerebrovascular 
abnormalities that result in cerebral blood flow disturbances and impaired perfusion (40). 
The predominant source of cerebrovascular abnormalities of small blood vessels in AD 
are cerebral amyloid angiopathy and arteriosclerosis (41). Although CAA of the Aβ type 
is commonly observed in patients with AD and mouse models of the disease (42,43), the 
in vivo relationship between CAA related blood flow alterations in the brain of AD 
patients and Aβ deposits has not been systematically studied. Understanding the 
contribution of cerebrovascular abnormalities to the progression of AD is an important 
step for the development of new treatment strategies to slow and/or prevent the 
progression of the disease. 
 
CAA is defined as the deposition of Aβ in the cerebral vessel walls (Fig 1.1b). The 
evidence for CAA in AD brain mainly comes from post-mortem studies (44,45). For 
example, Yamada has reported that among AD patients, the frequency of CAA was 87% 
(46). The CAA was associated with blood vessel wall disruption, loss of vascular smooth 
muscle cell and aneurismal vasodilation that lead to an increased incidence of CAA-
related cerebral haemorrhage (47).  
 
CAA usually affects cortical capillaries, small to middle-size arteries of the cerebral 
cortex and the leptomeninges (48). CAA may cause a failure in perivascular lymphatic 
drainage pathways, which drains interstitial fluid and solutes drain from the brain. 
Eventually, failure in drainage pathways could result in decreased clearance of Aβ from 
the brain (49). Finally, some evidence suggests that CAA could be an important cause of 
cerebral blood flow disturbances (50). There is a need for direct non-invasive in vivo 
methods to probe blood flow disturbances during AD development. Non-invasive 
visualization of these disturbances and correlation of them with in vivo plaque load could 
be an important step in the development of new therapies for the prevention of AD but 




1.1.2 White matter alterations in AD  
Along with grey matter pathologies, white matter microstructural alterations are also 
implicated in the pathogenesis of AD (51-55). The evidence for white matter alterations 
came mainly from neuropathological examinations of AD brain (52,54-57). Around 60% 
of the confirmed cases of AD showed white matter abnormalities, such as myelin 
breakdown (52). Although there is evidence that white matter abnormalities are 
associated with cognitive impairment, contribution of these abnormalities to the onset and 
progression of AD, however, remains unclear (58).  
 
There is converging evidence that different patterns of white matter abnormalities in 
corpus callosum, which is the largest white matter structure in the brain, are associated 
with AD progression (59). Since the corpus callosum plays an important role in 
functional connectivity and cognitive processing, abnormalities in this region may lead to 
impairment in connections between brain regions, and disturb cognitive process (60). The 
disconnection between brain regions can play a critical role in progression of AD 
pathophysiology (59). Even though multiple AD studies have reported microstructural 
changes in the corpus callosum (61,62), little is known about age-dependent changes and 
tissue characteristics of these abnormalities. Biochemical analyses of AD white matter 
revealed that increased Aβ load is accompanied by significant decreases in the amount of 
myelin basic protein, myelin proteolipid protein, cholesterol, and leads to increased total 
fatty acid content (57). In addition, neuropathological examination depicted 
abnormalities, such as gliosis, reduction of oligodendrocytes, partial loss of axons and 
myelin breakdown in AD white matter (51,52,54,55). To approach these changes in vivo, 
however, is challenging. There is a need for in vivo non-invasive techniques to monitor 
age-dependent microstructural changes in corpus callosum. Altered white matter integrity 
in corpus callosum might be an early key event in the development of AD pathology. 
Non-invasive measures may have the potential to follow deteriorating white matter 
integrity during normal aging and the development of AD and, thus, may be a useful 
marker to evaluate treatment success. 
 
The lack of histological correlation forms a limitation of in vivo studies. Therefore, 
animal models of AD can serve as valuable biological tools to characterize vascular and 
white mater abnormalities in vivo, and correlate these alterations with histology. 
Chapter 1 
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1.2 Mouse models of AD 
More than 200 early onset-FAD mutations have been reported in genes producing APP, 
PS1 and PS2 proteins (39). Based on mutated FAD genes, and mutations on the gene of 
microtubular associated protein tau, in vivo mouse models of AD have been developed. 
Several groups have combined APP, PS1, PS2 and/or MAPT mutations to generate 
double or triple transgenic mice (63). Transgenic mouse models of AD play a very 
fundamental role in the study of pathogenic mechanisms in AD and allow development 
of novel therapeutic approaches that ameliorate or prevent AD within the next decade 
(64). These models replicate various features of human AD including senile plaques, 
cognitive deficits and neurofibrillary tangles pathology (11). A brief summary of the 
most commonly used transgenic mouse models of AD is presented in Table 1.1 and an 
updated overview of these models is available on the following website, 
http://www.alzforum.org, which also shows mouse models based on late-onset AD 
genetic risk factors, such as apolipoprotein.   
 
Tg2576 is one of the most commonly used and well-characterized transgenic mouse 
models of the disease (Table 1.1) (65,66). This transgenic mouse line overexpresses a 
mutant human APP cDNA transgene with the K670M/N671L double mutation (also 
called Swedish mutation) under the control of the hamster prion protein promoter (65). 
These mutations lead to formation of soluble Aβ42 and Aβ40 peptides, resulting in Aβ 
plaque development. Aß deposits start to appear at approximately 9 months of age and 
are similar to those found in AD. The plaques become visible in cortical and limbic brain 
regions of Tg2576 mice together with indications of cellular inflammation and 
behavioural defects (67-69). Neuronal loss, including loss of cholinergic neurons is not a 
feature of Tg2576 mice whereas CAA and white matter abnormalities are well developed 
in this model (70,71). Furthermore, development of age-dependent memory defects as 
assessed by Morris water maze testing, was also demonstrated in this model (65). Many 
of these findings fit well with biochemical and epidemiological findings in AD. Even 
though mice carrying FAD mutations represent a very small percentage of AD cases 
(1%<), the development and progression of AD pathology in these mouse models is of 
great interest to researchers since mouse models of AD present many pathologic features, 
similar to those found in patients with LOAD (in which symptoms develop at age 65 or 
later). Future treatment strategies that are effective in transgenic mouse models carrying 




Over the past decade, in vivo non-invasive magnetic resonance based techniques, such as 
magnetic resonance imaging and spectroscopy, have emerged as a powerful means to 
monitor different biological processes longitudinally over time in transgenic mouse 
models of AD. Current efforts to extend the use of MRI and MRS to evaluate brain 
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development of treatments and provide a potentially efficient approach for investigating 
promising biomarkers and evaluating candidate therapies. In the following paragraph, a 
brief introduction of theory of MR-based techniques that were employed in this thesis, 
and their relevance to mouse imaging is presented. 
 
1.3 Magnetic resonance imaging 
 
Magnetic resonance imaging is a highly advanced non-invasive medical imaging 
technique, with a very high spatial resolution. It is commonly used in preclinical and 
clinical studies as a noninvasive tool to investigate the structural, biochemical and 
functional changes in the brain (77).  
 
The physical principles of MRI are based upon the nuclear magnetic resonance 
phenomenon, which was first experimentally demonstrated in 1946 independently by 
Purcell et al (78) and Bloch (79). NMR is a physical phenomenon in which nuclei in a 
magnetic field absorb and re-emit electromagnetic radiation. The nuclei with an odd 
number of neutrons or protons exhibit spin. One of the most abundant nuclei with spin in 
the human body is the 
1
H atom. The 
1
H nuclear magnetic response to an external 
magnetic field is one of the strongest found in nature. For this reason protons are the most 









nuclear magnetic moments corresponding with spin ½ and are also suitable for detection 
by magnetic resonance (77). However their sensitivity is not as high as for the proton.  
 
When nuclei possessing a spin are placed in an external magnetic field (B0), the nuclear 
spins behave like a compass needle or small magnet (Fig. 1.2). The different nuclear 
states produce a net magnetization vector Mz along the direction of B0 (Fig. 1.2b). When 
the magnetization is tilted away from the B0 direction by a radiofrequency pulse 
irradiation, the spins will precess around the magnetic field axis (z-axis) at a frequency 
proportional to the magnitude of the external field, according to the Larmor frequency in 
the MHz to GHz range, determined by γ, the gyromagnetic ratio. Protons have a higher γ 
(42.575 MHz/T) compared other nuclei of biomedical interest. When an alternating 
magnetic field (B1) is applied perpendicular to B0 by using RF at the Lamor frequency 
(resonant frequency), the nucleus absorbs the portion of this energy. Subsequently it 
induces a transition between different spin states. The spins, which have different 
possible energy states, absorb the energy. This phenomenon can lead to a full or partial 
inversion of the nuclear spin population, with an increase in the fraction of the higher 
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energy state spins at the expense of those in the lower energy states decrease. When B1 is 
applied in the presence of B0, the magnetization vector Mz will rotate away from the z-
axis towards the xy-plane or – z-axis (Fig. 1.2c). Immediately after the radio frequency 
signal is switched off, the nucleus reemits the absorbed energy and the polarization 
relaxes back to the original alignment (Figs. 1.3a, b). This return to equilibrium is 
referred to as relaxation. The recovery process of magnetization along the longitudinal 
axis is called T1 relaxation, spin-lattice relaxation or longitudinal relaxation (Fig. 1.3b). 
During this process an exchange of energy occurs between the spin system and the 





The number T1 represents the time it takes for 63% of the nuclear magnetization 
associated with the excited protons to realign with the B0 (80). The transverse (or spin-
spin) relaxation time T2 reveals loss of the net magnetization in the xy-plane, due to 
dephasing (Fig. 1.3c). During T2 relaxation, the energy is transferred between 
neighbouring nuclear spins. The number T2 represents the time for Mxy to drop to 37% of 
its original magnitude due to dephasing (80). During dephasing, the net magnetization in 
the xy-plane decays exponentially to zero over time. The rate at which this occurs is 
dependent on T2 and the T2 process is described as: 
. (1.2) 
 
 Figure 1.2: (a) Demonstration of MR 
basics. Protons have a magnetic 
moment, or “spin”. (b) When protons 
are placed in an external field B0, a 
large number of nuclei spins align 
parallel to the external magnetic field 
B0 (along the z-axis), resulting in a net 
magnetization vector Mz. (c).  
Application of a 90° RF pulse flips Mz 
into the xy-plane (perpendicular to B0), 
resulting in magnetization vector Mxy 
and phase coherence between spins. 




When an image is acquired, T1 or T2 or a 
combination determines the amplitude 
of the MR signal and intensity of the 
image. Relaxation time parameters form 
the basis of tissue contrast in MRI, 
which allows identification of white and 
gray matter regions. During a relaxation 
period, the nuclei lose energy by 
emitting their own RF signal. This NMR 
signal is referred to as the free-induction 
decay. In MRI, the FID signal is 
measured by a surface or volume coil 
placed on or around the object being 
imaged. This measurement is processed 
or reconstructed to obtain grey-scale 
MR images. The resonance condition forms the basis of MRI, which can form an image 
by representing a display of spatially localized signal intensities. The image formation is 
achieved in two steps. First a slice of tissue is selected for imaging. Subsequently the 
location of the signal is determined through the use of a nonuniform magnetic field 
created by magnetic field gradients, which causes the spin location to be encoded in 
terms of its Larmor frequency (77). The gradient field is parallel to B0 and its strength 
varies with position relative to B0. The gradient has three components, Gx, Gy, and Gz, 
associated with the x, y, or z spatial axis, respectively. When a magnetic field gradient 
along the z axis formed, the magnitude of the applied magnetic field changes in 
proportion to the z axis while remaining constant for any point in any xy plane (77). 
Application of the gradient field allows the spins to experience different field strengths, 
which depend on the location of the spins within the gradient field. The gradient direction 
(x, y, z) determines the slice orientation, whereas the gradient amplitude together with the 
RF pulse characteristics determine both the slice thickness and slice position. Two most 
commonly employed pulse sequences for MRI are the spin echo sequence and the 
gradient echo sequence (Figs 1.4a,b) (81,82).  
 
SE sequences use two RF pulses, an excitation pulse, which is a slice selective 90° pulse, 
and one or more 180° refocusing pulses that generate spin echoes. The two important 
parameters in a SE sequence are the repetition time and the echo time. TR is defined as 
the time between successive excitation pulses for a given slice. TE is the time from the 
 
Fig. 1.3. (a) Application of a 90
0
 radiofrequency 
pulse produces magnetization in the xy plane Mxy. 
When RF pulse is stopped, the nucleus reemits the 
absorbed energy and relaxes back to the original 
alignments at a rate determined by T1 (b) and T2 (c) 




excitation pulse to the echo maximum. This sequence can be adjusted to give T1- 
weighted, proton density and T2-weighted images. The images acquired with the SE 
sequence are less sensitive to susceptibility artifacts than the data obtained with gradient 
echo sequences. In the SE sequence the 180° refocusing pulse can correct the 
susceptibility-induced dephasing of spins from T2* effects (82). The GE sequence is used 
in a wide variety of imaging techniques, such as MR angiography. This sequence uses 
only a single selective pulse, which changes from 10° to 90°, in combination with readout 
gradient reversal. This sequence provides a fast imaging possibility with short TR (82).  
 
1.3.1 Rapid acquisition with relaxation-enhancement imaging 
Rapid acquisition with relaxation-enhancement imaging (83,84) is a fast magnetic 
resonance spin echo-imaging method. It is based on the Carr-Purcell-Meiboom-Gill echo 
train in which multiple spin echoes are generated by employing multiple 180° refocusing 
pulses. This imaging method delivers excellent T2 contrast, which makes this method 
ideal for screening in most neurodegenerative disorders. 
 
 
Figure 1.4: Simplified spin echo (top) 
and gradient echo (bottom) pulse 
sequence diagrams. The basic 
difference between gradient echo and 
spin echo imaging is related to the 
fact that echo formation is a result of 
a single RF pulse and gradient 
reversal while spin echo imaging uses 
two RF pulses, i.e., a second 180° 
pulse, for echo generation. As a 
result, the gradient echo signal 
intensity is determined by T‐decay 
and, contrary to the spin echo 
T2‐weighted signal intensity, field 
inhomogeneity effects are not 
refocused at the time of signal 
formation. DAQ reflects the period of 
data acquisition. Reproduced, with 
permission, from Markly and Leupold, 
2012 (81). © John Wiley & Sons, Inc. 
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The primary contrast in RARE is T2-based, however the contrast in the final image can be 
modified depending on the choice of TE, and TR. T2-weighted images usually have a 
long TR >1500 ms and long TE, whereas a T1-weighted image has a short TR <500msec 
and short TE. In a T2-weighted image, the elements with long T2 will appear bright, and 
elements with a short T2 will appear dark. TE refers to the time between the excitation 
pulses and the echo. A practical implementation of RARE imaging in visualizing 
Alzheimer’s Aβ plaques is demonstrated in Chapter 2. 
 
1.3.2  Magnetic resonance angiography 
Magnetic resonance angiography offers a non-invasive approach to visualize 
cerebrovasculature and blood flow defects. One well-established MRA technique is the  
time of flight angiography (Fig. 1.5), which is commonly employed for the clinical 
evaluation of many vascular diseases (85). This technique is based on a nuclear magnetic 
resonance phenomenon in flowing liquids (86). This phenomenon, known as the time-of-
flight effect, arises from the saturation of stationary tissue during RF pulse application, 
which leads to a net magnetization approaching zero and weak signal. The RF pulses, 
however, cannot fully saturate a flowing liquid, where the polarization is refreshed 
continuously with spins with full magnetization, and eventually this increases the signal 
(Fig. 1.4) (81,87). This phenomenon forms the basis of the contrast mechanism between a 
blood vessel and stationary tissue (85,87).  
 
The time of flight MRA method is sensitive to fast flowing blood. In this method, vessel 
visibility depends on several object parameters, such as velocity of blood flow, relaxation 
times (T1, T2, T2*) of tissue and vessel diameter, and the imaging parameters, such as flip 
angle, slice profile, thickness and orientation, voxel size or field of view, resolution, TR, 
and TE (85,88,89). For example, increasing TR and decreasing the flip angle increases 
the visibility of vessels with lower lumen diameter where the blood flow is slow (88,90). 
In addition, moving to higher fields can significantly improve vessel visibility. Higher 
magnetic field strengths provide a double advantage for vessel/tissue contrast (91). First, 
an increase in stationary tissue T1 value with increasing magnetic field strength provides 
better suppression of tissue signal. Second, higher magnetic field strength increases the 





flowing blood (91).The 3-D MRA acquired with 3D gradient echo sequences provides 
visualization of the large and small size arteries in a particular volume with a superior 
resolution (Fig. 1.4) (81,85,91). Additional post-processing of cross-sectional slices of 
these images with special techniques such as a maximum intensity projection algorithm 
allows 3D visual inspection of the vessel anatomy at an arbitrary view angle (92). 
Chapter 2 contains a practical implementation of this technique. 
 
Figure 1.5. In-flow enhancement in GRE imaging results in bright signal of blood entering the 
imaging slice. In combination with saturation of static tissue this effect can be exploited to provide 
high blood‐tissue contrast as in time of flight MR angiography. Vblood = Velocity of blood; TR = 
Repetition time; TE = Echo time; α = flip angle. Reproduced, with permission, from Markly and 




1.3.3 T2 relaxation mapping  
As described in the previous chapter, the relaxation times (e.g. T1 and T2) are intrinsic 
tissue parameters that are sensitive to changes in the biophysical water environment, and 
help determine the contrast in MRI (93). For example, myelin breakdown increases the T2 
relaxation time. Thus T2 mapping has been proposed as a sensitive tool to investigate 
microstructural changes in white matter during AD progression (See Chapter 3, 4). 
 
The T2 relaxation time can be measured using multi-echo data sets acquired during a spin 
echo, enabling time efficient multi-slice imaging. T2 can be calculated using different fit 
functions. In this thesis, to calculate T2 maps of brain regions, regions of interest were 
drawn manually on the images by using an image sequence analysis tool package 
(Paravision 5, Bruker), which uses a fit function [y= A+C*exp (-t/T2)], where A is the 
absolute bias, C represents the signal intensity, and T2 is the transverse relaxation time. 
Estimating true (absolute) T2 values of tissue is challenging in biological systems due to 
increased field inhomogenities and magnetic susceptibility differences, which lead to 
signal loss. The spin echo technique used in this thesis rephrases the signal before 
collection, which decreases the effect of susceptibility differences on the signal (81,82). 
Therefore the calculated T2 is closer to the true T2 values than for images acquired with 
traditional methods.  
 
1.3.4 Magnetic resonance spectroscopy 
Magnetic resonance spectroscopy is a specialized method that offers a non-invasive 
means for the characterization of metabolic composition of tissues from the particular 
region of interest in vivo. This method along with MRI has been commonly employed in 
preclinical studies to study a variety of neurodegenerative disorders such as Alzheimer’s 
disease. MRS and MRI are closely related techniques. The same scanner is used for both 
MRI and MRS. Both techniques use signals from the same nuclei, in particular 
1
H. One 
of the main differences between MRI and MRS is that while MRI provides information 
on the physical-chemical state of tissue and on motion, MRS provides only information 
about the chemical composition of tissue and is less sensitive than MRI. 
 
The MR spectra are acquired by applying a RF pulse via a surface or volume coil at a 




P, etc.) in 
the region of interest. When the excitation RF pulse is turned off, the spins relax to their 
equilibrium state by emitting RF waves. These RF waves are collected as an FID in the 
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time domain by the RF coil (94). The sensitivity of the experiment can be increased by 
repeating the experiment and accumulating the FIDs. The FIDs contain (1) intensity, (2) 
frequency, (3) half-life, or t½ and (4) phase information. The FID is converted to 
frequency-domain data (i.e. the spectrum) using a technique called Fourier transformation 
where the data are presented in the form of a one dimensional or two dimensional 
spectrum.  
1.4 Monitoring AD using MR- based techniques  
In recent years increasing effort has been directed towards the development of non- 
invasive high resolution in vivo neuroimaging methods to monitor pathological changes 
in AD brain. Two most commonly employed advanced imaging technologies are PET 
and MR-based techniques, such as MRI. Unlike PET, MRI uses non-ionizing 
radiofrequency pulses and a strong magnetic field to acquire brain images with high 
spatial resolution. With continuing developments in the precision of MRI, it is 
increasingly feasible to use these techniques in the study of subtle brain changes during 
AD progression (10,95).  
 
Currently a variety of MR based techniques is commonly employed to characterize the 
anatomical, functional, neurochemical and blood flow changes observed during AD 
progression. For example, progressive cerebral atrophy, such as hippocampal atrophy, is 
a characteristic feature of AD, which can be detected with structural MRI (10,96,97). 
Non-invasive, in vivo methods to image Aβ plaque-load would be very valuable for 
monitoring Aβ formation with age in the same patient, and to evaluate the success of 
treatments for plaque clearance (98). MRI can detect Aβ plaque-load with higher spatial 
resolution compared to PET without using ionization radiation. Theoretically, MRI has 
the potential to resolve individual Aβ plaques, which range from 2 to 200 m in size (99). 
Until now two main strategies have been employed to detect Aβ plaques in AD brain. 
These strategies involve contrast-enhancing agents, which bind to Aβ plaques, and 
susceptibility artefacts. In vivo MRI methods to image Aβ plaques without contrast 
agents in human AD patients are underway (100) but are currently not available in 
clinical magnetic fields. Recent ex vivo and in vivo higher field MRI studies using 
susceptibility artefacts have visualized Aβ plaques in the brain of AD mice as 
hypointense signals (98,101,102). These studies suggested that the signal hypointensities 
observed on MRI images represent Aβ plaques, containing metals, particularly iron. In 
addition, reduction of the water content in Aβ plaques can be the source of signal 
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hypointensities observed in MRI (103). Also, indirect MRI techniques, such as diffusion 
kurtosis imaging, magnetization transfer contrast and relaxation time maps have been 
employed to detect amyloid load in AD brains (10).  
 
Microstructural changes, such as white matter degeneration, which accompany AD 
development, can be detected by intrinsic relaxation time parameters or DTI. DTI maps 
diffusion processes of water molecules in the brain, which serves as useful tools to detect 
changes in white matter integrity. DTI is being tested in an attempt to distinguish patients 
with AD from healthy elderly individuals (10). The neurobiological substrate of diffusion 
changes in AD remains unresolved. It remains unclear whether DTI has sufficient 
sensitivity to separate AD patients from controls, and is awaiting sufficient validation to 
be accorded into wider clinical use (10). Recent studies depicted that in vivo quantitative 
T2 relaxation measurements are capable of characterizing white matter abnormalities in 
demyelinating disorders such as Multiple Sclerosis (104). However, few studies have 
employed T2 measurement to asses white matter integrity in AD (105). Studies to 
characterize these changes longitudinally are missing. Functional MRI task free and task-
based methods, which measure brain activity, are under evaluation to investigate their 
potential to discriminate different states of AD from healthy elderly individuals. In 
particular, a task free method, namely the resting state functional connectivity MRI 
method is increasingly employed to investigate subtle brain network abnormalities in AD 
(106). Loss of intra-network connectivity in large scale networks, including the default 
mode network, dorsal attention network, control network, salience network, and sensory 
motor network, has been shown in AD using the rs-fc MRI method, suggesting that 
soluble and/or insoluble Aβ causes disordered neural communication (106). The 
diagnostic accuracy of this method is under evaluation.  
 
Biochemical changes in the brain can be measured by employing MR spectroscopy, 
which provides information about brain chemistry. Proton (
1
H) MRS, among other 
spectroscopy methods, is one of the most commonly employed in vivo MR techniques for 
diagnosis of AD. This method has great potential to be used in clinical diagnosis of AD 
in the near future. For example, a decrease in NAA/mIns ratio provides very high 
sensitivity and specificity to distinguish AD from healthy individuals (95,107,108). 
Several cerebrovascular alterations, such as CAA, accompany AD neuropathology in AD 
(42,46,70). Cerebral blood flow abnormalities can be detected non-invasively in vivo in 
transgenic mouse models of AD (109) and human AD patients (110) by a variety of 
methods such as MRA and arterial spin labelling. A brief overview of MR based 
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techniques for visualizing blood flow and white matter abnormalities to assess AD 
pathology is given below. 
 
1.4.1  MRA to detect blood flow abnormalities  
The role of cerebrovascular abnormalities in the etiology of AD is increasingly becoming 
a topic of research (111). How CAA related abnormalities in cerebral blood flow 
contribute to the onset and progression of AD, and the interrelationship between these 
abnormalities and parenchymal amyloid load, however, remains unclear. In vivo non-
invasive methods to visualize the blood flow abnormalities in brain are needed to address 
these questions.  
 
Cerebrovascular blood flow abnormalities can be detected without contrast agent 
administration via MR-based techniques such as MRA and ASL. MRA of the mouse 
brain can be performed in spontaneously respiring animals. Determining the basal 
perfusion alterations in mice using ASL techniques is, however, challenging. Stable 
physiological conditions are warranted during in vivo scanning. This can be obtained by 
intubating and ventilating the animal, allowing a more controlled setting. However, these 
procedures are not routinely performed. MRA has been employed to investigate vascular 
alterations in a variety of mouse models of AD (109,112,113) and in clinics (114,115), 
the resolution of these studies, however, was hampered by the use of low magnetic field 
strengths. The MRA studies at ultra high magnetic field strengths, such as 17.6 T, which 
can provide better visualization of moderate to smaller vessels, are missing. The ability of 
the ultra-high field MRA to detect small flow disturbances makes it attractive as a 
diagnostic tool in AD (109). The application of this method in a mouse model of AD at 
17.6 T is presented in Chapter 2. 
 
1.4.2 T2 measurements to assess white matter abnormalities  
Tissue relaxation time parameters, such as T1 and T2, are sensitive to the biophysical 
environment, and can provide tissue specificity allowing enhanced characterization of 
pathological tissue (116). Thus a variety of aging and AD studies have employed 
relaxation time data in order to detect changes in tissue integrity (117-123). However, 
changes in relaxation values of white matter of AD brain with age and correlation of 
these values with AD pathological features, such as amyloid load and demyelination, is 




Table 1.2: Summary of T2 relaxometry studies in AD mouse models of AD and wild-type mice 
 
BS= Brainstem, C= Cingulate cortex, CB= cerebellum, CC= Corpus callosum, Cpu= Caudate putamen, CX= Cortex, 
GM= Gray matter, HC = Hippocampus, FCX= Frontal cortex, OCX= Occipital cortex, pCX= Pariatal cortex, RSP= 
Retrosplenial Cortex, , TH= Thalamus, SB =Subiculum, SB/PSB= Subiculum/parasubiculum, TPCX= Temporoparietal 
cortex, V= Ventricle, vCX =Visual cortex,WT= White matter . a Some mice were studied cross-sectional.  
 
A variety of transgenic mouse models of AD have been used to investigate the correlation  
between intrinsic relaxation values and AD pathology (e.g., demyelination, gliosis, Aβ 
plaque deposition). An overview of these studies in AD mice is depicted in Table 1.2.  
 
The changes in gray matter are well characterized by these studies using relaxation 
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white matter. There is evidence that altered white matter integrity, such as demyelination, 
is an early event in the course of the AD, but the nature of these changes and their 
contribution to the onset and progression of the disease remains unclear (52,133-136). 
There is an emerging need for detection of these changes in vivo with MRI, which has 
potential to aid early diagnosis of AD. T2 values are sensitive to myelination and 
demyelination processes (124).  
 
Thus, T2 measurements can serve as a sensitive non-invasive tool to longitudinally 
monitor subtle microstructural changes in corpus callosum and other white matter 
regions. However, a proper longitudinal study, which follows T2 changes in white matter 
integrity of AD mice models, is missing. 
 
1.4.3 Ultra-high field MRI in mouse models of AD 
Transgenic mouse models of human diseases have been commonly employed in 
biomedical research for testing treatments and monitoring disease progression. Being a 
non-invasive method, MRI allows longitudinally monitoring of structural and functional 
changes in these murine models of human diseases. The small size of the mouse brain 
however, has considerable limitations such as low signal-to noise ratio for a given 
measurement time. To overcome these limitations, several strategies can be employed 
such as conventional signal averaging, using a cryogenic radio frequency coil, or moving 
to higher magnetic field strength. In particular, the use of ultra-high magnetic fields 
(≥7T) in MRI and MRS will be highly beneficial in order to obtain well-defined chemical 
shift spectra, larger data acquisition rates, higher-resolution and signal-to-noise ratio 
(137). Currently the best available horizontal MRI system operates at field strength of 
14.1 T, whereas vertical systems are at much higher field strength (≥17.6 T). Use of ultra-
high systems might cause a paradigm shift in preclinical AD studies through the in vivo 
observation of metabolism and subtle microscopic tissue changes. Many MR based 
techniques benefit from ultra-high fields. In particular, MRA clearly benefits from high 
magnetic field. Increased T1 relaxation time and high magnetization at higher fields 
provides improved higher vessel-to-tissue contrast and the signal- to-noise ratio that may 
contribute to the improved quality of MRA (138). Thus abnormalities in smaller vessels 
can be monitored without the use of contrast enhancing agents.  In addition to increased 
SNR, in vivo localized MRS, which provides the unique prospect of longitudinally 
monitoring brain metabolism in living animals or humans, benefits from high magnetic 




Relaxation time parameters (e.g. T1 and T2) are known to change substantially with 
increasing field strength in biological tissues, but the amount of change depends, among 
other factors, on the biophysical water environment and the presence of metal ions such 
as iron in such a way that it cannot be estimated accurately with a theoretical calculation 
(139) . Thus, an accurate determination of proton relaxation times with ultra high field 
strength MRI is an essential first step in exploring the capabilities of ultra high field MRI. 
While such values have been reported in lower field strength, to our knowledge 
normative T2 values of healthy mouse brain for 17.6 T are currently not available (See 
Chapter 4).  
1.5 Thesis scope 
An advanced characterization of AD pathology can be achieved by application of non-
invasive in vivo imaging methods, such as MRI, to monitor the disease progression 
longitudinally in transgenic mouse models of AD. In particular in vivo imaging of these 
mice models at ultra high magnetic field strengths can permit a better understanding of 
the underlying cellular mechanism of AD. This knowledge can be used to develop 
potential biomarkers and promising treatment strategies to impede and/or prevent the 
disease progression.  
 
There are important developments in AD translational research, especially with respect to 
the in vivo imaging of vascular defects and white abnormalities using MRI in transgenic 
mouse models of AD. AD is linked to abnormalities in the vascular system such as CAA. 
Although CAA is very common in the advanced stages of AD, its contribution to the 
onset and progression of AD remains unclear. In addition, the in vivo relationship 
between Aβ plaque deposition in brain tissue and its correlation with blood flow 
alterations is unknown. Longitudinal high-resolution MR studies to monitor blood flow 
abnormalities are required to study blood flow abnormalities and to investigate whether 
they are associated with Aβ plaque deposition. Furthermore there is a need for monitoring 
white matter changes in corpus callosum with age during AD development. The 
converging evidence suggests that different patterns of white matter abnormalities in 
corpus callosum are associated with AD progression (59). These changes might be an 
early biomarker for AD. How and when the integrity of white matter decreases in corpus 




Since ultra-high field systems are increasingly used in AD research, there is a need for 
accurate determination of proton relaxation times at 17.6 T to explore the capabilities of 
ultra high field MRI. While such values have been reported at lower field strength, to our 
knowledge normative T2 values of healthy mouse brain for ultra high magnetic field 
strengths (17.6 T) are currently not available. These values can serve as normative values 
against which disease related relaxation changes can be assessed in mice. 
 
The aim of this thesis is to implement and optimize MR based techniques, namely MRA 
and T2 relaxometry at high and ultra high magnetic field (i.e. 9.4 and 17.6 T) to 
longitudinally monitor blood flow and white matter abnormalities in a mouse model of 
AD to establish potential neuroimaging biomarkers. 
 
In Chapter 2, high resolution MRA at 17.6 T has been optimized and successfully 
implemented to longitudinally monitor morphological changes in cerebral arteries in a 
Tg2576 mouse model. These changes were correlated with Aβ plaque development.  In 
Chapter 3 in vivo T2 changes were longitudinally monitored in the corpus callosum of 
the Tg2576 mice. Since T2 values have been shown to be sensitive to axonal injury, 
gliosis and demyelination, probing changes in T2 values will provide a sensitive marker 
of dynamic microscopic changes in the corpus callosum, and will eventually yield new 
insights into the pathology underlying AD. In Chapter 4, regional T2 values of the 
healthy mouse brain were established at 17.6 T, and regional brain T1 and T2 changes 
were followed with age. The estimates of in vivo T1 and T2 will be useful to optimize 
pulse sequences for optimal image contrast at 17.6 T and will serve as baseline values 
against which disease related relaxation changes could be assessed in mice. Chapter 5 
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2 Monitoring blood flow alterations in the Tg2576 
mouse model of Alzheimer’s disease* 
2.1 Abstract 
Many neurodegenerative diseases including Alzheimer’s disease are linked to 
abnormalities in the vascular system. In AD, the deposition of Aβ peptide in the cerebral 
vessel walls, known as cerebral amyloid angiopathy is frequently observed, leading to 
blood flow abnormalities. Visualization of the changes in vascular structure is important 
for early diagnosis and treatment. Blood vessels can be imaged non-invasively by MRA. 
In this study we optimized high resolution MRA at 17.6 T to longitudinally monitor 
morphological changes in cerebral arteries in a Tg2576 mouse model, a widely used 
model of AD. Our results at 17.6 T show that MRA significantly benefits from the ultra-
high magnetic field strength especially to visualize smaller vessels. Visual and 
quantitative analysis of MRA results revealed severe blood flow defects in large and 
medium sized arteries in Tg2576 mice. In particular blood flow defects were observed in 
the middle cerebral artery and in the anterior communicating artery in Tg2576 mice. 
Histological data show that Aβ levels in the vessel wall may be responsible for impaired 
cerebral blood flow, thereby contributing to the early progression of AD. To our 
knowledge this is the first ultra-high field MRA study monitoring blood flow alterations 
longitudinally in living Tg2576 mice, consequently providing a powerful tool to test new 
therapeutic intervention related to CAA in a mouse model of AD.   
2.2 Introduction 
Alzheimer’s disease is the most common form of dementia with no effective treatment or 
definitive ante mortem diagnostic test. The neuropathologic features of AD include the 
occurrence of Aβ-containing plaques, neurofibrillary tangles, decreased synaptic density, 
and loss of neurons (1,2). In addition, cerebrovascular abnormalities coexist with these 
pathological features of AD. In particular, the deposition of amyloid in the cerebral vessel 
walls, known as cerebral amyloid angiopathy, is frequently observed, leading to blood 
flow abnormalities in AD (3,4). Small to medium-sized arteries and arterioles are the 
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most frequently affected vessels by CAA in AD (5-7). Though CAA is very common in 
the advanced stages of AD, its contribution to the onset and progression of AD is 
unknown.  
 
The evidence for blood flow disturbance in AD comes mainly from postmortem studies 
(8,9). Yamada (2002) has reported that among AD patients (n = 82), the frequency of 
CAA was 87%, whereas the frequency of CAA in elderly non-AD (n = 119) patients was 
only 35%. CAA of Aβ type, defined by the accumulation of β-amyloid peptide (Aβ) in 
cerebral vessels, is the most common form of CAA in elderly population as well as 
patients with AD (10).  Currently in vivo diagnosis of CAA relies on detecting indirect 
symptoms such as hemorrhage, microbleeding and abnormal vascular reactivity (4,11). 
Although positron emission tomography in combination with Pittsburg compound, has 
been shown to detect CAA in AD patients (4), the need to use ionizing radiation for PET 
and unspecificity of Pittsburg compound for distinguishing between parenchymal and 
vascular Aβ plaques impede the use of this method on a large scale.   
 
Transgenic mouse models of AD have been used to understand how CAA related blood 
flow abnormalities contribute to the onset and progression of AD (12-18). Ex vivo studies 
in human and in transgenic mouse models have reported similar observations regarding 
CAA related morphological changes in vascular structures leading to blood flow defects 
in AD. Recently, an upregulation of the angiogenic vascular endothelial growth factor by 
cortical vascular endothelial cells in 21-month-old transgenic Tg2576 mice has been 
observed suggesting a role of vascular endothelial growth factor in formation of vascular 
Aβ and mediating CAA (19,20).  However, direct in vivo methods to probe blood flow 
disturbance during AD in mice are highly challenging. In vivo MR techniques currently 
used for AD evaluations in humans and mouse models of AD are in a state of progression 
with continued reassessment for enhanced diagnostic accuracy (21,22). Non-invasive MR 
imaging techniques, such as in vivo MRA, have shown great potential to study blood flow 
defects in APP23 and APP/PS1 mouse models of AD (23-25). In this technique 
shortening of the effective T1 of moving blood provides the vessel contrast with 
stationary tissue (26). While the global architecture of the cerebral vasculature could be 
detected in both APP23 and APP/PS1 mice by in vivo MRA at 4.7 T magnetic field 
strength, further improvement in visualization is desirable, especially for detection of 
small arteries with low blood flow rate. The small size of the mouse brain has 
considerable limitations for MRA in visualizing cerebral vasculature with high spatial 
resolution and signal-to-noise ratio at low magnetic field strength (≥4.7 T). The T1 
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relaxation time of tissue increases with the field strength (27). Increased T1 relaxation 
time and high magnetization at higher fields provides improved signal-to-noise ratio and 
higher vessel-to-tissue contrast that may contribute to the improved quality of MRA (28). 
Therefore, moving to high (such as 9.4 T) or ultra-high (such as 17.6 T) magnetic field 
can significantly improve visualization of cerebral vasculature and blood flow 
abnormalities in mouse models of AD as well as for other neurodegenerative diseases. 
Tg2576 is one of the most widely used transgenic mouse models of AD (29). In this 
model accumulation of Aβ in cerebral vessels starts between 9-12 months of age and 
severity of CAA increases during aging (30-34). Reports on MRA for this mouse model 
are lacking. In addition, the in vivo relationship between amyloid plaque deposition in 
brain tissue and its correlation with blood flow alterations is not clear.  
 
The aim of this study was to: (1) achieve improved visualization of cerebral vasculature 
by optimizing and applying in vivo MRA at 17.6 T magnetic field strength; (2) detect AD 
related blood flow defects in cerebral arties in Tg2576 mice; and (3) longitudinally 
follow, in vivo amyloid plaque deposition in brain tissue and its correlation with CAA 
related morphological changes in cerebral arteries and blood flow alterations in the same 
Tg2576 mice with age. 
2.3 Materials and Methods 
2.3.1 Mice 
In this study transgenic Tg2576 mice developed and described by Hsiao et al. (1996) 
were used as model of AD. The mice contained as transgene the human amyloid 
precursor protein (APP695) with the Swedish double mutation (K670N, M671L) under 
control of a hamster prion protein promoter (29). Three founder mice were kindly 
provided by Dr Karen Hsiao Ashe (University of Minnesota) and used for further 
breeding. Mice heterozygous for the transgene and wild-type littermates were on a 
C57BL/6 x SJL background. At the age of four weeks transgeneity was identified by 
polymerase chain reaction of tail DNA as described elsewhere (29). The N2 generation 
mice of both genders were studied at the ages of 12–18 months. Age-matched non-
transgenic littermates served as controls. In addition, C57BL/6 mice (9 months old) were 
used for optimization studies. All of the animal experiments were approved by the 
institutional animal care and animal use committee of the University of Leiden in 




Histological analyses were performed to assess amyloid deposits and CAA in Tg2576 
mice by following the procedure as described previously (21). The mice were decapitated 
and brains were fixed in 4% buffered paraformaldehyde (Zinc Formal-Fixx, 
ThermoShandon, UK) for 48 h. Following fixation brains were dehydrated and embedded 
in paraffin. Subsequently coronal sections (5 m thick) were carefully cut using a 
vibratome while maintaining as much as possible the same spatial orientation of the 
mouse brain as in the MRI experiments. To detect Aβ, brain sections were subjected to 
immunohistochemistry using anti-Aβ (6E10), anti-Aβ40 (BC40) or anti-Aβ42 (BC42). 
Immunolabeling was visualized by using the ABC kit (Vectastain) according to the 
manufacturer’s instructions. 
2.3.3 MRI 
All measurements were conducted on a vertical wide bore 9.4 T or 17.6 T Bruker 
spectrometer with a 1000 mTm
-1
 actively shielded imaging gradient insert (Bruker 
Biospin GmbH, Germany). A birdcage RF coil (inner diameter 2 cm) was used. The 
system was interfaced to a Linux PC running XWinNMR 3.2 and Paravision 5.0 (Bruker 
Biospin GmbH, Germany) software. 
 
All in vivo MR imaging studies were conducted as previously described (21). Before MR 
imaging, the mice were anesthetized with 2% isoflurane (Forene, Abott, UK), in air (0.3 
l/min) and oxygen (0.3 l/min). During scanning the isoflurane concentration was 
maintained between 1 and 1.5% to keep the breathing of the animal at a constant rate of 
~50 breaths per minute. Animals were placed in a birdcage RF coil with a special mouse 
head mask, which was used to administer the anesthetic gas during MR experiments. A 
respiration sensor, connected to a respiration unit, was placed on the abdomen of the 
mouse, to monitor it’s respiration rate during the MR imaging. The respiration unit was 
connected to a computer having Bio-SAM respiration monitoring software (Bruker 
Biospin, Germany). The body temperature of the mouse was kept constant by pumping 
warm water through the gradient system. The rectal body temperature of the mouse 
during scanning was measured to be 35±1°C.  
 
T2-weighted MR images were acquired with a multislice RARE (35) sequence at 9.4 T. 
Coronal images were obtained with a slice thickness of 0.5 mm. A resolution of 78x78 
μm was achieved within an acquisition time of ~25 min. The imaging parameters used for 
the RARE sequence were: TE = 11.6 ms (effective TE = 23.33 ms); TR = 6 s; FA = 90°, 
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averages = 4, RARE factor (echo train length) = 4; FOV = 2.00 × 2.00 cm
2
 and image 
matrix = 256 × 256. Quantification of Aβ plaque load in MR images was done as 
described earlier (21).   
2.3.4 MRA 
TOF angiograms were obtained using a 3D gradient-echo sequence. To find the optimum 
combination of parameters for TOF-MRA at 17.6 T, variable flip angle (FA) and TR 
parameters of the 3D TOF gradient echo sequence were systematically varied to obtain 
the best image quality in a reasonable imaging time. The following parameters were used: 
TE = 1.86 ms; FOV = 15 X 15 X 15 mm; matrix size= 128 X 128 X 128; FA = 10°, 15°, 
20°, 30°, 40° or 50°; TR  = 15, 20, 30, or 40 ms.  
 
Optimized scan parameters used to acquire high-resolution 3D-MRA of transgenic mice 
and non-transgenic littermates were as follows: TE = 1.86 ms; FOV = 17 X 17 X 17 mm; 
matrix size = 256 X 192 X 192; FA = 20°; and TR = 20 ms. All data were zero-filled to 
256 X 256 X 256.  
 
Three-dimensional TOF MRA was compared at 9.4 T and 17.6 T. All imaging 
parameters were kept the same at both magnetic fields. Imaging parameters were TE = 
1.86 ms; TR = 20 ms; FA = 20°. All data (matrix size 256 X 192 X 192) were zero-filled 
to 256 X 256 X 256. The total acquisition time of 3D-TOF was ~9 min. Three-
dimensional views were obtained by generating MIP using Paravision 5 software (Bruker 
Biospin, GmbH, Germany).  
 
Identification of cerebral arteries was performed by inspecting the angiograms under 
various angles and comparing the vessels to the anatomical atlas of Dorr et al. (36) and 
previous reports in the literature (25,37-40).  
 
2.3.5 Image analysis and quantification  
The severity of the vascular abnormalities in Tg2576 mice and non-transgenic control 
mice was evaluated by visual assessment as well as by a semi-quantitative analysis. 
Visual assessment of MCA was based on the pointing system as described earlier (25) 
According to this system, blood flow abnormalities were graded on the basis of the 
number and extent of signal voids detected on the MR angiograms. A flow disturbance 
was counted when a decrease of the signal was visible on the scan, but the signal 
intensity at the level of the artery did not yet reach background level. A void was counted 
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when the signal intensity at the level of the artery reaches the background level. 
Furthermore a distinction was made between a small void and an extended void. The 
grades were defined as follows: (1) flow disturbance visible, but the artery shape was 
unaltered; (2) one or two small signal voids: a small signal void was defined as a void 
with a maximum length of twice the diameter of the artery; (3) more than 2 small signal 
voids;  (4) one extended signal void: an extended void was defined as a void with a 
length larger than twice the diameter of the artery; (5) a combination of small and 
extended voids; and (6) artery was partially or completely missing.   
 
For the semi-quantitative method, the average contrast-to-noise ratio and signal-to-noise 
ratio were calculated from the coronal slices (n = 5-9) of the MRA data set. Three ROIs 
were selected in each slice: (1) an ROI manually delineated in the vessel contour on 
cross-sectional slices; (2) an ROI of the background brain tissue without vessels (BG); 
and (3) an ROI of the surrounding air. The average standard deviation of the ROI in 
surrounding air was defined as noise (σ). The CNR of each region was calculated as: 
CNR = (sROI-sBG)/σ (air). The SNR was calculated as: SNR = sROI/σ (air). “s” refers to 
average signal intensity within the selected area. Signal intensity of ROI placed on the 
vessel was calculated above a threshold value corresponding to s(BG)+[0.1x s(BG)]. 
 
The means and standard deviations of each region were calculated. The statistical 
comparisons were made by pooling all slice measurements from all the datasets in a 
given sample group and performing one-tailed and/or two-tailed Student’s t-test. 
Statistical significance was assigned for P values < 0.05. 
2.4 Results and Discussion 
2.4.1 Optimization of MRA at 17.6 T 
The 3D TOF MRA sequence was optimized at 17.6 T to visualize cerebral arteries in 
living mouse. To find the optimum combination of parameters for TOF MRA at 17.6 T, 
radiofrequency pulse TR and pulse FA were steadily varied.  
 
Fig. 2.1 shows the effect of varying FA and TR on CNR of MCA (Fig. 2.1A) and azPA 
(Fig. 2.1B). As is clear from this figure, MCA, which is one of the large vessels with 





Fig. 2.1. Optimization of 3D TOF-MRA at 17.6 T magnetic field strength. (A) The effect of 
varying the radiofrequency pulse flip angle (FA) and inflow time (repetition time, TR) was 
evaluated on contrast to noise ratio (CNR) of middle cerebral artery (MCA) (A) and azygos 
pericallosal artery (azPA) (B). The effect of varying the FA on the CNR of MCA and azPA 
measured at a constant TR of 20 ms (C). Vessels having higher blood flow such as MCA were 
better visualized at higher FA (30°), however smaller vessels such as azPA having low blood 
flow were better visualized at smaller FA (15°-20°). (D) Slice of a 3D data set indicating the 
region of interest for which CNR evaluation was performed (1= vessel; 2= background brain 
tissue; 3= surrounding air). The optimization was performed on three mice, with nearly identical 
results. For clarity, the plots are from a single specimen. The values are the mean ± SD (error 
bars) over five slices. 
 
of FA (20°-50°) and TR (15-40 ms). However small vessels such as azPA are better 
delineated at smaller FA (20°). While a longer TR offers greater CNR, the TR of 20 ms 
had been chosen as optimum to obtain reasonable resolution in a relatively short scan 
time for subsequent measurements. The relationship between CNR and FA (10°-50°) at 





Fig. 2.2. Coronal (A), sagittal (B) and transverse (C) projection of high-resolution MIPs of a 3D-TOF 
angiogram of a mouse cerebrovascular system revealing arterial anatomy at 17.6 T magnet field 
strength. The following arteries were clearly identified: (1) Olfactory artery (OlfA); (2) Anterior 
communicating artery (AComA); (3) Anterior cerebral artery (ACA); (4) Middle cerebral artery (MCA); 
(5) & (10) Internal carotid artery (ICA); (6) Facial artery (external Maxillary artery);(7) Palatine 
portion of pterygopalatine (PPP); (8) Posterior cerebral artery (PCA); (9) Maxillary artery; (11) 
Pterygo portion of pterygopalatine; (12) Caudal cellebellar artery;(13) A branch of common carotid 
artery; (14) Vertebral artery (VA); (15) Common carotid artery (CCA); (16) Ophthalmic artery; (17) 
Anterior azygos cerebral artery (azACA); (18) Azygos pericallosal artery (azPA); (19) Superior 
cerebellar artery (SCA); (20) Basilar artery (BA); (21) Middle internal frontal artery; (22) Anterior 
internal frontal artery; and (23) External carotid artery (ECA). 
 
3D data set of MRA showing the region of interest used for estimation of CNR of vessels 
with respect to background brain tissue and surrounding air is shown in Fig. 2.1D. Fig. 
2.1 depicts a high resolution MRA of a 14-months-old mouse along the coronal (A) and 
sagittal (B) and transverse (C) directions acquired in 9 min using optimized sequence 
parameters at 17.6 T. Many small and medium size vessels were nicely delineated at 17.6 
T within this short scan time.  
 
2.4.2 Field dependence 
Fig. 2.3 compares the angiogram of the vascular system of the same wild-type mouse 
imaged at 9.4 T (Fig. 2.3A) and 17.6 T (Fig. 2.3B). In general MRA at 17.6 T revealed 
enhanced visualization of vessels compared to the data collected in a field of 9.4 T, 
especially for small vessels. For example, branches of azACA are better resolved at 17.6 






Fig. 2.3. Angiogram in sagittal view of same 9-month-old wild-type mouse imaged at 9.4 T (A) and 
17.6 T (B) magnetic field strengths. Arrows indicate vascular branches, which are better resolved at 
17.6 T as compared to 9.4 T. Comparison of SNR (C) and CNR (D) of ACA, MCA and PPP vessels 
estimated at 9.4 T and 17.6 T. Both CNR and SNR in all three vessels were higher at 17.6 T as 
compared to 9.4 T. Values are expressed as mean ± SD (error bars). Two-tail student T test, *P 
<0.05, **P <0.01, n = 3. 
 
(a) and SNR (b) of vessels including MCA, ACA and PPP. The calculated SNR (Fig. 
2.3C) of all three vessels are significantly higher at 17.6 T as compared to 9.4 T. The 
SNR of MCA, ACA and PPP were ~50%, ~47% and ~33% higher at 17.6 T than at 9.4 T, 
respectively. MCA and ACA also showed significantly higher CNR (~70-80%) at 17.6 T 
than at 9.4 T (Fig. 2.3D). The superior contrast at 17.6 T could be attributed to longer T1 
of background tissue as well as greater magnetization of inflowing blood (41). The longer 
T1s of tissues provide better background suppression, which allows improved 
visualization of smaller distal vessels with MRA. The observed increase in SNR was less 
than expected for the higher field of 17.6T. This could be due to increased susceptibility 
effects and larger field inhomogeneity at higher magnetic field. Since SNR is inversely 
proportional to the square root of T1, longer T1 at higher field also has an inverse effect on 
SNR (42). Nevertheless the substantial increase of vessel SNR at 17.6 T is offering the 
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possibility to either increase the spatial resolution or to shorten scan times for future 
mouse MRA studies. 
 
2.4.3 Evaluation of vascular alterations in control and Tg2576 mice with age 
To evaluate and compare the in vivo vascular alterations in control and Tg2576 mice and 
to follow changes over time, we applied high resolution MRA at 17.6 T. In general blood 
flow alterations detected on TOF-angiograms were more frequent in Tg2576 mice as 
compared to control mice. In particular, the overall decrease in the brightness of arteries 
and alterations such as flow voids and vessel signal loss were more visible in Tg2576 
mice as compared to control mice. Fig. 2.4 (A and B) shows representative angiograms of 
two 18-month-old Tg2576 mice. The numbers on the angiogram indicate the appointed 
score to the level of severity of alterations. The higher the score, the more severe the 
alteration was. For example, a flow disturbance without apparent change in vessel shape 
is visible in AComA (score 1 in Fig. 2.4A); A small signal void was observed at the 
origin of AComA (score 2 in Fig. 2.4B); More than two small voids in the same artery 
were observed in MCA on both sides (score 3 in Fig. 2.4B); An extended void can be 
seen in the small branch of CCA on both sides (score 4 in Fig. 2.4A); A combination of 
an extended void and several small signal voids was observed in the small branches of 
carotid artery on both sides (score 5 in Fig. 2.4B). Signal was no longer visible for the 
pterygo portion of the pterygopalatine artery (score 6 in Figs. 2.4A and B). Fig. 2.4C 
shows the enlarge view of these alterations.  
 
In general, MCA was one of the most altered vessels in the TOF-angiogram of Tg2576 
mice. A comparison of the alteration mean scores in MCA in Tg2576 and control mice 
with age is shown in Fig. 2.4D. The changes in the MCA alteration score in control and 
Tg2576 mice were insignificant at the age of 14 and 16 months while became 
significantly higher (~57%) at the age of 18 months in Tg2576 mice as compared to the 
control mice (Fig. 2.4D). The abnormalities in MCA in Tg2576 mice, detected by MRA 
in this study, are consistent with in vivo cerebral blood flow alterations observed in MCA 
in human AD patients (43,44). In these patients, stenosis and cerebral hypoperfusion have 
been reported in the MCA. Fig. 2.5 (A and B) compares 3D angiogram and its source-
slice data set of control and a Tg2576 mouse. Severe decrease of signal intensity can be 






Visibility of alterations in individual slices of MRA data sets validates the changes seen 
in 3D MIP in Tg2576 mice. An age-dependent evaluation of CNR changes was 
performed in the source data images for every mouse for MCA and AComA (Figs. 2.5C 
and D). In both control and Tg2576 mice, an overall decrease in vessel CNR was 
observed with age. However, the decrease in CNR was more significant in Tg2576 mice 
than in control mice, in particular at the age of 18 months (Figs. 2.5C and D). A 3D 
representation of age-dependent changes seen in AComA in control and Tg2576 mice is 
shown in Fig. 2.5E. The arteries such as ACA, and OlfA in Tg2576 mice also showed a 
decreasing trend in CNR as compared with control mice, although this decrease did not 
reach statistical significance (supplementary Fig. 2.1S). Age-dependent increase in blood 
flow defects was also observed in a small branch of common carotid artery in Tg2576 
mice (Fig.2.2 S). 
 
Thus, our results show that blood flow alterations in Tg2576 mice can be very well 
detected with MRA at 17.6 T and can be followed longitudinally in the same mice with 




Fig. 2.4. (A, B) Angiograms collected in the 17.6 T magnet, of 18-month-old transgenic mice showing 
various level of severities of morphological changes appointed in 3D MIP. The number indicates the 
appointed score to the level of severity of alterations. For example: 1= a flow disturbance (as seen in 
AComA in image A); 2= a small signal void (as observed at the origin of AComA in image B); 3= more 
than two small voids in the same artery (as observed on the MCA on both sides in image B); 4= an 
extended void (as observed in the external carotid artery on both sides in image A); 5= a combination of 
an extended void and several small signal voids (as observed in the external carotid artery on both sides 
in image B); 6= the signal is no longer visible (as shown at the pterygo portion of the pterygopalatine 
artery in image A and B). The enlarge view of alterations is shown in C). (D) MCA alteration mean score 
in control and Tg2576 mice with age. Values are mean ± SE (error bars); one-tail student T test; *P 
<0.05; n = 4. 
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with cerebrovascular abnormalities reported in human AD patients (43,44). These 
findings suggest that Tg2576 is a valid mouse model for studying CAA related blood 
flow abnormalities in vivo. The hypointensities seen in 3D MIP of the mouse brain might 
be caused by a number of interrelated factors such as changes in vessel morphology 
(narrowing, compression, partial occlusion etc) and/or complex blood flow patterns 
(turbulent flow, reversal, acceleration or very slow blood flow) (23,25). Any of these 
factors can lead to loss of signal within cerebral arteries. Beckman et al. (2003) used the 
corrosion casts method to identify the underlying structural changes in the 
cerebrovascular system of APP23 AD mouse and showed that morphological anomalies 
of the vessel, such as constrictions and/or narrowing, occur at the sites where altered 
 
 
Fig. 2.5. Representative MIP images and source-slice data sets of an 18-month-old control (A) and 
Tg2576 mouse (B). Tg2576 mouse exhibited severe blood flow alteration at one of the AComA as 
depicted by arrow (b) which was not visible in control mice (a). The slices of 3D angio data collected 
in the 17.6 T magnet indicating the regions used for the signal intensity evaluation for control (c, e) 
and Tg2576 (d, f) mice. Severe decrease of signal intensity was observed in AComA and MCA in 
Tg2576 mice. (C) Age-dependent changes in contrast-to-noise ratio (CNR) of AComA (C) and MCA 
(D) in control and Tg2576 mice. One-tail student T test was used for statistical evaluation. *P <0.05 
and **P <0.01. The number of animals per age is as follows: control mice: age 14th month (n = 8), 
16th month (n = 6), and 18th month (n = 6); Tg2576 age 14th month (n = 8), 16th month (n =7), and 
18th month (n = 6).  (E) Age-dependent changes in AComA in a control mouse (a−c) and a Tg2576 




perfusion were detected by MRA (24). More recently the study of Thal et al. (2009) has 
signified the association of CAA with cerebral blood flow disturbance seen in MRA in 
APP23 mice (18). The blood flow alterations in Tg2576 seen in the present study may be 
associated with CAA related elevation of Aβ levels in the vessel wall (31). Figure 2.6 
shows the angiogram of an 18 month-old wild-type and a Tg2576 mouse, indicating flow 
disturbance in the branches of the MCA in Tg2576 mice (Fig. 2.6A-D). Histological 
staining of Aβ confirmed the presence of CAA in the territory of the pial branches of the 
MCA of the Tg2576 mouse, but not in the wild-type mouse (Fig. 2.6 E-F), suggesting a 
causal role of CAA on the blood flow alterations monitored by MRA. In addition, the 
immunohistochemistry also shows large prevalence of the Aβ40 isoform in cerebral 
vessel walls of Tg2576 mice, as compared to the Aβ42 isoform (Fig. 2.7A-C). These 
results are consistent with previous reports showing that dense plaques and CAA in 
Tg2576 mice are predominantly composed of Aβ40 (33,45) and that Aβ40 could play a 





Fig. 2.6. Angiogram in sagittal view of an 18-month-old wild-type (A) and a Tg2576 mouse (B). The 
magnified subsampled area of the wild-type mouse shows the visible blood flow signal from branches 
of middle cerebral artery (MCA) (C), however in the Tg2576 mouse a marked decrease in blood flow 
signal intensity from the branches of the MCA was observed (D). Histological section of the brain of 
an 18-month-old wild-type (E) and a Tg2576 mouse (F), stained with monoclonal anti-Aβ (6E10) 
antibodies. CAA was detected in the territory of the pial branches of the MCA of the Tg2576 mouse, 






Fig. 2.7. CAA detected in the brain sections of 23-month-old Tg2576 mouse stained with anti Aβ40 (A) 
and anti Aβ42 (B). Magnified subsample areas of A (a-e) and B (f-j) are depicted in (C). Aβ-positive 
plaques in the cortex and hippocampus are shown with arrowheads and CAA affected blood vessels 
are shown with arrows. Plaques attached to vessels in brain sections stained with Aβ42 are depicted in 
the enlarged view at the right. Scale bars in A and B, 1mm. 
The magnetic susceptibility effects due to the presence of iron in the amyloid plaques 
near or around the vessels may create signal voids in MRA that may have no connection 
with flow disturbance (25). However, we did not observe any severe iron deposition in 
Tg2576 mouse brain (Fig. 2.3S), thus ruling out the contribution of iron-related 
susceptibility effects to the signal voids seen in the MRA images for this mouse model.  
 
The frequency and severity of CAA in Tg2576 mice are age related (31). The CAA first 
accumulates in the anterior region of the brain in large arteries around the 10th month of 
age and then progress toward smaller vessels distal from the midline and lateral side of 
the brain (16 months) and finally at an advanced age of 23 months almost all the vessels 
are affected by CAA (31). Our in vivo age-dependent MRA studies have shown severe 
impairment of blood flow starting only at the older age of 18 months, (Fig. 2.4D and Fig. 
2.5 C, D) suggesting that after a certain level of elevation of Aβ, cerebrovascular 
abnormalities can be observed with MRA in these Tg2576 mice. Consistent with this 
suggestion, extensive loss of vascular smooth cells correlated with severity of the CAA 
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was reported in older Tg2576 mice (30,46). These results confirmed that mild amounts of 
CAA have little or no effect on vessel wall integrity. However, as amounts of CAA 
increase significant disruptions of vessel wall integrity develop, including considerable 
losses of vascular smooth cells (46). In addition, a more recent MRA study reported 
blood flow alterations in the thalamic vessels of APP23 mice and histology results 
showed capillary CAA association with vessel occlusion and cerebral blood flow 
disturbances in APP23 mice (18). Despite these findings, in another MRA study drastic 
cerebral blood flow disturbance was observed in APP23 mice brain, which did not 
correlate with CAA levels, such that deposits of amyloid plaques were not observed in 
arteries located in the circle of Willis (48). It was suggested that blood flow abnormalities 
in the brain might have been caused by soluble Aβ in these mice (48,49). Another study 
has proposed that small amyloid aggregates associated with the microvasculature lead to 
morphological and architectural alterations of the vasculature before amyloid plaques 
appear; resulting in altered local blood flow in APP23 mice (15). 
 
Blood flow alterations associated with increased CAA levels are more severe in APP23 
mice (24), compared to the Tg2576 mice (this study). If mainly soluble Aβ in the blood 
caused severe blood flow alterations in APP23 mice, this effect should have been very 
drastic in Tg2576 mice, due to the fact that Tg2576 mice have higher levels of soluble Aβ 
in the blood (24,50,51). It was stressed that the reason for the relatively rare occurrence 
of CAA in Tg2576 mice and the significant occurrence in APP23 mice can be related 
with expression levels and genetic background of the transgenic lines (49).  
 
Potential causal factors for cerebral blood flow abnormalities observed in our study and 
other studies may not be limited to Aβ levels (soluble and/or insoluble), but also other 
factors that are independent of CAA level might have been contributed blood flow 
abnormalities (24,25,34,52,53). Vascular oxidative stresses have been related to 
alterations in cerebrovascular dysfunction in AD (54). Superoxide-producing enzyme 
NADPH oxidase, a major source of ROS, appears to play a central role in 
cerebrovascular dysfunction (55). Recently, it has been reported that 12- to 15-month-old 
Tg2576 mice lacking the catalytic subunit, Nox2, of NADPH oxidase do not develop 
oxidative stress, cerebrovascular dysfunction, or behavioural deficits, suggesting a 
potential role for ROS in CAA-induced vessel dysfunction (55). Subsequently it was 
reported that cerebrovascular dysfunction in aged Tg2576 mice can be fully rescued by 
antioxidants and the peroxisome proliferator-activated receptor agonist pioglitazone (56). 
In addition, Aβ induced endothelial dysfunction, which is characterized by impaired 
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endothelium-dependent vasodilation due to an reduced endothelial production of 
vasodilators, such as nitric oxide and an increased release of vasoconstrictors including 
endothelin-1, might be playing a role in cerebral flow abnormalities in AD (57). In spite 
of this multitude of findings, the causal factors for blood flow abnormalities occurring in 
vessels of Tg2576 mice and other AD mouse models require further investigation. Being 
able to follow progression of vascular abnormalities in vivo can increase our 
understanding of such causal factors.  
 
2.4.4 Age-dependent increase in Aβ plaque load 
To explore the temporal relationship between in vivo plaque load development in the 
brain tissue and blood flow abnormalities, we performed high-resolution µMRI in 
parallel to MRA in the same Tg2576 mice with age. Fig. 2.8A depicts in vivo T2–
weighted MR images of the brain of a 16 and 23-month-old control and Tg2576 mouse. 
Hypointense regions corresponding to Aβ plaques were observed in Tg2576 mouse brain 
and increased with age (Fig. 2.8A.). As expected Aβ plaques were not visible in control 
mouse brain. The quantitative analysis of Aβ plaque load in cortex in Tg2576 mice 
between 12 and 18 months of age is shown in Fig. 2.8B. A marked increase in plaque 
load was observed in Tg2576 mice with age. However, the increase in plaque load was 
 
 
Fig. 2.8. (A) In vivo T2–weighted MR images of the brain of a 16 (a, c) and 23 (b, d) month old 
control (a, b) and Tg2576 mice (c, d) showing that hypointense regions corresponding to Aβ plaques 
increased with age in the Tg2576 mouse. (B) Age-dependent changes in Aβ plaques load in a 




more rapid between 16 and 18 months of age (Fig. 2.8B). This time course matches well 
with the drastic increase in blood flow defect between 16 and 18 months of age seen in 
same Tg2576 mice (Fig. 2.4D and Fig. 2.5C, D). These results indicate that severity of 
amyloid plaque deposition in the brain parenchyma and cerebrovascular deposition of Aβ 
may be closely linked.   
 
In conclusion, in this study we optimized and performed 3D TOF MRA at 17.6 T for 
detailed in vivo assessment of mouse cerebral vasculature and to compare the age- 
dependent alteration in cerebral vasculature in control and Tg2576 transgenic mouse 
models of AD. Our results show that MRA significantly benefits from the ultra-high 
magnetic field strength (17.6 T) especially to visualize smaller vessels. Age-dependent 
blood flow abnormalities were observed in vivo in MCA and AComA of 18-month-old 
Tg2576 mice. In addition, histology data showed cerebrovascular amyloid deposition in 
Tg2576 mice. These results show that vascular abnormalities observed in this study are 
part of the pathological alterations developed by Tg2576 mouse models of AD. MRA 
studies at ultra-high magnetic field provide a powerful non-invasive tool to test the 
effectiveness of putative disease-modifying therapeutic intervention in mouse model of 
AD in vivo.   
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Fig. 2.1S. Age dependent changes in contrast-to-noise ratio (CNR) of ACA (A) and 
OlfA (B) in wild type and Tg2576 mice. The number of animals per age is as follow: 
wild type age 14th month (n = 8), 16th month (n = 6), and 18th month (n =4); 
Tg2576 age 14th month (n = 8), 16th month (n =7) and 18th month (n = 6). One-tail 
student T test was used for statistical evaluation. Although a decreasing trend in 
CNR was observed with age in Tg2576 mice as compared with control mice, the 





Fig. 2.2S. Age dependent changes in a small artery branched from CCA in wild 
type (a, b, c) and Tg2576 (d, e, f) mouse imaged at the age of 14 (a,d); 16 (b, e) and 






Fig. 2.3S. Aβ plaques and iron in the adjacent brain sections of an 18-
month-old Tg2576 mouse. Brain sections were stained with (a) an Aβ 
antibody or (b) Perl’s reaction following 3, 3-diaminobenzidine 
enhancement. Arrows indicate presence of iron. Only few plaques contain 
iron. Since no severe iron deposition was seen in Tg2576 mouse brain, we 
can rule out the possible contribution of iron-related susceptibility effects 
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3 Longitudinal monitoring of transverse relaxation 
time (T2) changes in the corpus callosum region of 
a mouse model of Alzheimer’ disease* 
3.1 Abstract 
The corpus callosum is the largest commissural fiber connecting left and right 
hemisphere of the brain. Emerging evidence suggests that a variety of abnormalities, 
detected in the microstructure of this white matter fiber, can be an early event in 
Alzheimer's disease pathology. However, little is known about tissue characteristics of 
these abnormalities and how these abnormalities evolve during AD progression. In this 
study, we measured in vivo the magnetic resonance T2 to longitudinally monitor changes 
in tissue integrity and abnormalities related to myelination and demyelination processes 
in corpus callosum of AD mouse models. The most striking finding of our study was 
significant elongation of T2 values in the corpus callosum at 10, 14, 16 and 18 months of 
age, compared to age-matched wild-type mice. In contrast, grey matter regions 
surrounding the corpus callosum, such as the cortex and hippocampus, showed a 
significant T2 decrease compared to wild-type mice. Histological analyses clearly 
revealed demyelination, gliosis and amyloid-plaque deposition in the corpus callosum. 
Our results suggest that demyelinating and inflammatory pathology may lead to 
prolonged relaxation times and can mark an early event during Alzheimer’s disease 
progression. To our knowledge, this is the first in vivo T2 study assessing microstructural 
changes with age in the corpus callosum of the Tg2576 mouse model. It demonstrates the 
application of T2 measurements in non-invasively detecting tissue degradation of corpus 
callosum, which can be early event in disease progression. 
3.2 Introduction 
Alzheimer’s disease is the leading neurodegenerative disorder in the elderly with no 
effective treatment. The neuropathological features of AD include extracellular deposits 
of Aβ, intraneuronal fibrillary changes, gliosis, decreased synaptic density, 
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demyelination, and brain regional atrophy (1,2). Neuropathological diagnosis of AD is 
still based on the presence of primarily gray matter alterations due to abundant Aβ 
deposition in the region. In recent years, a strong interest in white matter pathology, e.g. 
demyelination, seen in AD has developed (3-8). Corpus callosum, made of dense 
myelinated fibers, is the major white matter tract of the brain, and plays an important role 
in functional connectivity and in cognition (9). It has been suggested that corpus callosum 
can be susceptible to myelin breakdown during AD progression (4). Demyelination in 
corpus callosum might already be present in the early stages of AD (10,11), however its 
role in disease onset and progression remains unclear. There is an emergent need for new 
studies to monitor corpus callosum changes longitudinally in order to clarify how and 
when the integrity of corpus callosum changes in AD.  
 
The evidences for white matter abnormalities seen in AD came mainly from postmortem 
studies (8,12-16). These studies reported reduction of oligodendrocytes, in parallel with 
axonal degeneration, activation of glial cells and decrease in myelin integrity in white 
matter of AD patients. To determine changes in myelin integrity and its underlying 
causes in vivo, however, is challenging.  
 
The T2 measurement serves as a powerful non-invasive MRI tool to explore subtle 
microstructural changes in white and gray matter regions of brain (17,18). The T2 values 
are sensitive to pathology related changes such as demyelination, axonal injury, gliosis 
and iron deposition. For example, myelin breakdown increases the free tissue water, and 
thus increases T2 (19,20), whereas accumulation of iron in tissue decreases T2 (21). Due 
to the sensitivity of T2 to tissue pathology, the changes in T2 values of various brain 
regions have been commonly used as a marker in evaluations of aging and a variety of 
brain disorders such as AD (22-24). In a recent study, an increased T2 for the genu of the 
corpus callosum was significantly correlated with an age-related slowing in cognitive 
processing speed in healthy elderly people (25), suggesting myelin integrity in the corpus 
callosum as a surrogate marker of assessing cognitive decline. However, little is known 
about age-related T2 changes in the corpus callosum region of AD patients (26), and its 
correlation with pathology such as Aβ deposition and gliosis remains unclear. Studies 
using transgenic mouse models of AD have the potential to clarify these in vivo changes. 
 
The transgenic mouse models of AD, which develop AD like pathology (e.g. 
accumulation of Aβ plaques), serve as valuable biological tools to observe changes in the 
integrity of the white matter (e.g. corpus callosum) and clarify underlying 
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neurobiological factors (27,28). Although assessment of in vivo brain tissue relaxation 
time in the AD mice models has great potential to detect abnormalities in the corpus 
callosum and other white matter regions, till now measurements of relaxation times for 
these AD models has been mainly restricted to gray matter regions of the brain, e.g. the 
cortex and hippocampus, which are prominently affected by Aβ pathology (24,29-32). A 
summary of previous T2 studies in a variety of AD mouse models and healthy mice are 
presented in Table 1.2 (Chapter 1). Only two cross-sectional studies in the APP-PS1 
mouse model of AD have measured relaxation time changes in the corpus callosum 
(31,32). However, longitudinal monitoring of T2 changes with age in the corpus callosum 
regions are missing. The Tg2576 is a widely used model of AD. This transgenic AD 
mouse develops several pathologies, including overproduction of human Aβ40, Aβ42 and 
gliosis, which fit well with biochemical and epidemiological findings in the disease (33). 
In addition, Tg2576 mouse models develop progressive learning and memory impairment 
accompanied by Aβ plaque deposition starting at 9-12 months of age (33). Consequently 
Tg2576 mice serve as a truly useful model to study a variety of aspects of AD related 
pathology. The T2 measurements in corpus callosum of Tg2576 mice have not been 
attempted so far.  
 
The aim of this study was to probe in vivo T2 changes longitudinally in the corpus 
callosum region of the Tg2576 mice with age. Since T2 values have been shown to be 
sensitive to axonal injury, gliosis and demyelination, probing changes of the T2 will 
provide a sensitive marker of dynamic microscopic changes in the corpus callosum, and 
will eventually yield new insights into the pathology underlying AD. In this study, along 
with the T2 for the corpus callosum, values of gray matter regions were also measured. 
Histological and immunohistochemical analysis were also performed for determining 
potential neurobiological factors contributing changes in T2.  
3.3 Materials and Methods 
3.3.1 Mouse models 
 
In the present study Tg2576 mice were used as a transgenic model of AD (33). These 
mice contain as the transgene the human amyloid precursor protein (APP695) with the 
Swedish double mutation (K670N, M671L) under control of a hamster prion protein 
promoter (33). The founder mice were kindly provided by Dr Karen Hsiao Ashe 
(University of Minnesota) and used for further breeding. Mice heterozygous for the 
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transgene and wild-type littermates were on a C57BL/6 x SJL background. At the age of 
four weeks transgeneity was identified by the polymerase chain reaction of tail DNA, as 
described elsewhere (33). The N2 generation mice of both genders were studied at the 
ages of 10–18 months. Age-matched non-transgenic littermates served as controls. In 
addition, C57BL/6 mice (4 months old) were used for optimization studies. All of the 
animal experiments were approved by the institutional animal care and animal use 
committee of the University of Leiden in accordance with the NIH Guide for the Care 
and Use of Laboratory Animals.  
 
3.3.2 Histology 
Histological analyses were performed to assess Aβ deposits, gliosis and demyelination in 
Tg2576 and wild-type mice. After the MRI experiments, the animals were sacrificed and 
the brains were fixed in 4% buffered paraformaldehyde (Zinc Formal- Fixx, 
ThermoShandon, UK) for 48 h. Following fixation, brains were dehydrated and 
embedded in paraffin. Subsequently coronal sections (5 μm thick) were carefully cut 
using a vibratome while maintaining as much as possible the same spatial orientation of 
the mouse brain as in the MRI experiments. These sections were stained with H&E and 
LFB to compare white matter changes between wild-type and Tg2576 mice, using 
standard histology protocols (34). LFB dye is commonly used for the demonstration of 
normal myelin. Myelin fibers are seen blue under the light microscope (34). To stain 
activated astrocytes, brain sections were subjected to immunohistochemistry using a 
primary polyclonal anti-GFAP antibody (DAKO) as described earlier (35). To detect 
activated microglial cells and macrophages, a primary polyclonal anti-IBA-1 antibody 
1:1000 (Wako Chemicals, Neuss, Germany) was used as described previously (35). To 
detect Aβ, brain sections were subjected to immunohistochemistry using monoclonal 
anti-Aβ42 (BC42), anti Aβ40 (BC40) and polyclonal anti-Aβ 40–42 as described earlier 
(35). Immunolabeling was visualized by using the ABC kit (Vectastain) according to the 
manufacturer's instructions. Images of the histological sections were obtained using a 
Leica DM RE HC microscope interfaced to a Leica DC500 3CCD digital camera. 
 
3.3.3 MRI experiments 
Magnetic resonance imaging was performed using a 400 MHz (9.4 T) vertical 89-mm 
bore magnet equipped with a 1 Tm
-1
 actively shielded imaging gradient insert (Bruker, 
Germany). A birdcage transmit/receive RF coil (inner diameter 2 cm) was used. The 
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system was interfaced with a Linux PC running Topspin 2.0 and Paravision 5.0 imaging 
software (Bruker Biospin GmbH, Germany). 
 
All in vivo MRI studies were performed as previously described (35,36). A special mouse 
head mask was used to fix the head of the animal inside a 20 mm birdcage RF coil and to 
administer the anesthetic gas during MR experiments. The mice were initially 
anesthetized with 2% isoflurane (Forane, Abott, UK) in air (0.3 L/min) and oxygen (0.3 
L/min). During scanning the level of anesthetic was maintained between 1 and 1.5% to 
keep the breathing of the animal at a constant rate of ~50 breaths per minute. During 
scanning, the respiration rate was constantly monitored using a respiration sensor, (placed 
on the animal’s abdomen) connected to a respiration unit. The respiration unit was 
connected to a computer with Bio-SAM respiration monitoring software (Bruker Biospin, 
Germany). The mouse’s body temperature was kept at a constant temperature by 
pumping warm water through the gradient system. Cooling of the gradient was performed 
by circulating water. The rectal body temperature of the mouse during scanning was 
measured to be 32±1°C. 
 
T2 values were acquired with the MSME sequence that is based on the CPMG sequence, 
where transverse magnetization of a 90º pulse is refocused by a train of 180º pulses 
generating a series of echoes (37,38). The following imaging parameters were used: NA 
= 2; Number of slices = 10 with a slice thickness of 1.0 mm and an interslice thickness of 
1.5 mm; Number of echoes = 12 with echo spacing = 8.5; A TR = 1.5 s with an effective 
spectral bandwidth = 69.44 kHz; FOV = 2.0 x 2.0 cm; Matrix size = 256 x 256; This 





. The total acquisition time for the experiment was 12 min 48 s. To study the 
dependence of T2 on the CPMG refocusing interpulse interval (), the T2 measurements 
were performed using the MSME sequence with 16 echo and 5 different refocusing 
interpulse intervals, namely 6.6, 8.5, 10.5, 15.5 and 18.5 ms. The last few echoes were 
discarded to provide five comparable temporal sampling windows, 6.6-79.4 ms, 8.5-
85.50 ms, 10.5-94.5 ms, 15.5-93.0, 18.5-92.5 ms acquisitions, respectively. To minimize 
the contribution of the partial volume effect from cerebrospinal fluid, the ROIs were 
checked carefully on images collected with thin slices using T2-weighted MR images 
acquired with a rapid acquisition with the RARE sequence (39), with following 
parameters: TR = 6000 ms; TE = 17 ms; FOV = 2.0 x 2.0 cm; Matrix size= 256 x 256; 
NS = 30, with slice thickness 0.5 mm; interslice thickness = 0.5 mm. To establish the 
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test–retest reliability of T2 measurements, the same C57BL/6J mice (n= 5) were scanned 
twice on two subsequent days. 
 
3.3.4 Data processing 
 
3.3.4.1 Estimation of T2  
To calculate T2 maps of selected regions, ROIs were drawn manually on the images by 
using an image sequence analysis tool package (Paravision 5, Bruker), which uses a 
monoexponential fit function [y= A+C*exp (-t/T2)], where A stands for the absolute bias, 
C is the signal intensity, and T2 represents the transverse relaxation time as usual. ROIs 
were manually defined for the white matter regions such as the corpus callosum, cerebral 
peduncle, anterior commissure, and the gray matter regions including the hippocampus, 
cortex, thalamus, hypothalamus, caudate-putamen and olfactory bulb on a T2-weighted 
image using the “Allen Brain Atlas” with the brain explorer program (http://mouse.brain-
map.org) as the reference atlas. For all animals, the T2 was the mean of the ROIs drawn 
on the right and left sides of the brain, except for the corpus callosum. Two consequent 
slices were used to delineate the corpus callosum.  
 
3.3.4.2 Statistics 
The paired and/or unpaired two-tailed student’s t-test was used to compare mean values. 
Statistical significance was assigned for values of P < 0.05. The reliability of the 
measurements was assessed by computing the ICC2,1 using a 2-way random effects 
ANOVA model and the absolute agreement definition (40,41). An ICC close to 1.0 
indicates high reliability. The ICC can only be 1.0 if the measures are identical. 
3.4 Results  
3.4.1 Longitudinal monitoring of T2  changes 
Fig. 3.1A shows the ROIs, used to quantify the age-dependent T2 relaxation time changes 
in various gray and white matter regions of wild-type and transgenic mouse brain. Before 
the longitudinal T2 study, the test-retest reliability of in vivo T2 measurements using the 








Fig. 3.1. (A) Anatomical T
2
-weighted MR coronal slices of a mouse brain, showing various brain 
regions for T2 measurements acquired with the RARE sequence at 9.4 T. (B) Test-retest reliability 
measurements were performed for a variety of brain regions 
a
ICC = intraclass correlation using a 2-





 (ms) means from five subjects, SD, paired t test = session 1 and session 2 
results collected from the same mice were compared. P > 0.05 in all cases for paired t test. There is a 
one-day interval between session 1 and session 2. Corpus callosum (CC), hippocampus (HC), cortex 
(CX) and thalamus (TH), Cerebral peduncle (CP), anterior commissure (AC), Hypothalamus (HT), 




Fig. 3.1B shows test-retest reliability results of in vivo T2 measurements in multiple brain 
regions. Reliability was found to be very high for corpus callosum (ICC = 0.84, P < 
0.05), hippocampus (ICC = 0.90, P < 0.05), cortex (ICC = 0.72, P < 0.05) and thalamus 
(ICC = 0.85, P < 0.05) regions. The ICC values for other regions did not reach statistical 
significance. The systematic error was checked by a paired t-test and no systematic error 
was observed between measurements. The dependence of T2 on the CPMG refocusing 
interpulse interval () was investigated for cortex and corpus callosum regions (Fig. 
3.1S). No statistically significant effect of the interpulse interval in the range of interest 
(6.6 and 8.5 ms) was observed on the T2 of the cortex and of corpus callosum. Thus 
confirming that the changes observed in T2 values in individual brain structures depend 
on changes in tissue properties rather than magnetic field disturbances.  
 
Fig. 3.2 shows the variation of the T2 for various brain regions including the corpus 
callosum of Tg2576 and wild-type mice with age. As is clear from this figure, T2 values 
in the corpus callosum region of Tg2576 mice were significantly higher compared to the 




Fig. 3.2. In vivo T
2
 changes in the corpus callosum (CC), cortex (CX), hippocampus (HC) and 
thalamus (TH) regions of the wild-type (WT) and Tg2576 mice at the age of 10, 14, 16 and 18 
months. Values are expressed as mean T
2
 in ms ± SD (error bars). Two tailed student t- test, **P < 
0.01, ***P < 0.001 significant from T
2
 of control mice. The number of animals per age is as follows: 
control mice: age 10 months (n = 8), 14 months (n = 8), 16 months (n = 6) and 18 months (n = 6); 







Fig. 3.3. Age-dependent in vivo T
2
 changes of corpus callosum region of the wild-type (WT) 
and Tg2576 (TG) mice. Values are expressed as mean T
2
 in ms ± SD (error bars) (95% 
C.I.). Two tailed student t-test, **P < 0.01, ***P < 0.001 significant from T
2
 of WT mice. 
The number of animals per age is as follows: control mice: age 10 months (n = 8), 14 
months (n = 8), 16 months (n = 6) and 18 months (n = 6); Tg2576: age 10 months (n = 8), 
14 months (n = 9), 16 months (n = 8) and 18 months (n = 7).  
 
months of age (P < 0.001). The T2 values of the hippocampus and cortex of the Tg2576 
miceshowed, however, a significant decrease (P < 0.05) compared to the age-matched 
wild-type mice at 18 months of age. No significant differences in T2 values were observed 
in the thalamus regions between the Tg2576 and wild-type mice.  
 
Fig. 3.3 shows a comparison of the alteration in T2 with age for the corpus callosum in 
Tg2576 and wild-type mice. The changes in T2 values in the corpus callosum in the wild-
type and Tg2576 mice were statistically significant at the all ages. As is clear from this 
figure, a trend of increase in T2 values of Tg2576 with age was evident between the ages 
of 14 to 18 months but not in wild-type mice. The level of increase in T2 in the corpus 
callosum of Tg2576 mice relative to wild-type mice is 4.09%, 5.45% and 6.40 % for 14, 
16, and 18 months of age, respectively.  
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3.4.2 Histological evaluation 
To examine AD related demyelination and other structural changes, histological analysis 
was performed. Fig. 3.4 (A, B) shows brain slices stained with LFB stain for staining 
myelin. A marked demyelination was noted in the corpus callosum region of the 18 
months old Tg2576 mouse as compared to the wild-type mouse (Figs. 3.4A and B). 
Furthermore, H&E stain revealed clear vacuolation and demyelination in the corpus 
callosum region of the Tg2576 mouse (Fig. 3.4D), but not in the wild-type mouse (Fig. 
3.4C).  
 
Fig. 3.5 shows brain slices stained for reactive gliosis (astrocytosis and/or microgliosis) 
in the control (Figs. 3.5A and B) and Tg2576 (Figs. 3.5C and D) mice. Anti-IBA-1 
antibody staining was used to identify microglial activation (Figs. 3.5A and C), whereas 
anti-GFAP antibody staining was used to check the astrocytosis (Figs. 3.5B and D). As is 
clear from these figures both astrocytosis and microgliosis were observed in the corpus 
callosum region of the 18 months old Tg2576 mouse brain but not in the wild-type 
mouse. Black arrows shown in Figs. 3.5 C and D show co-localized reactive microglial 
and astrocytic cells. Fig. 3.6 depicts the results of Aβ staining in the brain sections of the 
18 months Tg2576 mouse. Both Aβ42 (Fig. 3.6C) as well as Aβ40 (Fig. 3.6D) positive 
plaques were clearly present in the territory of the corpus callosum of Tg2576 mouse but 




Fig. 3.4: Histological section of the brain of an 18 months old wild-type (A, C) and a Tg2576 (B,D) 
mouse, stained with the Luxol fast blue (A, B), and hematoxylin and eosin (C, D). Demyelination and 
vacuolation in the corpus callosum region of transgenic mouse (B and D) is more prominent 
compared to the wild-type mouse (A, C) as can be clearly seen (arrows) in the magnified subsample 







Fig. 3.5. Histological section of the brain of an 18 months old wild-type (A, B) and a Tg2576 (C, D) 
mouse, stained with anti-GFAP (A, C), anti-IBA1 (B, D) antibodies. Activated astrocytes (C) and 
microglial activity (D) were detected in the CC region of the transgenic mouse brain as can be clearly 




Fig. 3.6. Histological section of the brain of an 18 months old wild-type (A, B) and a Tg2576 (C, D) 
mouse, stained with anti-Aβ42 (A, C), anti-Aβ40 (B, D) antibodies. Aβ-positive plaques (C, D) were 
detected in the CC regions of the transgenic mouse brain, as can be clearly seen (arrows) in the 





microglia cells were clustered usually around Aβ deposits as is clear from Fig. 3.7, which 
reveals the co-registration of Aβ deposition with activated glial cells for the 18 months 
old Tg2576 mouse. 
 
Fig. 3.8 depicts histological staining of the corpus callosum region of 29 months old 
Tg2576 mouse. Severe Aβ plaque deposition (Fig. 3.8A-C) as well as a marked increase 
in the amount of GFAP (Fig. 3.8D), IBA-1 (Fig. 3.8E) and demyelination (Fig 3.8F) were 
observed at 29 months of age, compared with 18 months old Tg2576 mice. The 
expression of GFAP and IBA-1 is visible in the same region where the Aβ plaques are 
deposited. Interestingly Aβ40 positive plaques were larger in size than Aβ42 positive 
plaques in the corpus callosum of 29 months old mice.  
 
 
Fig. 3.7. Histological section of the brain of an 18 months old Tg2576 mouse stained with anti-GFAP 
(A), anti-IBA1 (B) anti-Aβ42 (C), anti-Aβ40 (D) antibodies. Note reactive astrocytes (A) and microglial 





Recent evidence suggests that the integrity of the corpus callosum changes prior to 
development of severe AD pathology (42). How and when these integrity changes occur 
and their contribution to the disease progression in vivo remains unclear. In this study, T2 
relaxation measurements were used to probe subtle microstructural changes in the corpus 
callosum in vivo. The study was followed longitudinally to monitor changes in the 
integrity of corpus callosum during AD progression in the same Tg2576 mice with age, 
and the results were supported by histological examinations of demyelination, gliosis and 
Aβ plaques deposition. 
 
Fig. 3.8. Representative histological sections of the corpus callosum of a 29 months old 
Tg2576 mouse stained with anti-Aβ42-40 (A), anti-Aβ40 (B), anti-Aβ42 (C), anti-IBA1 (D), 
anti-GFAP (E) antibodies and myelin reactive stain (F). Arrows depict microglial activity and 
Aβ deposits in the corpus callosum of the Tg2576 mouse. The areas where Aβ deposits appear 
show marked demyelination (Arrows). Scale bars: 80 μm.. 
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3.5.1 Longitudinal T2 analysis  
T2 changes were followed longitudinally in the corpus callosum region of the wild-type 
and Tg2576 mice between 10 and 18 months of age. The major finding of this study was 
a significant prolongation of the T2 in the corpus callosum, reflecting significant 
microstructural changes in Tg2576 mice as compared to wild-type mice. The elongation 
of T2 values observed in our study is well in line with previous human studies where 
increase of the T2 was reported in corpus callosum with increasing dementia score (26). 
Interestingly, the T2 of corpus callosum was already significantly longer for 10 months 
old Tg2576 mice, compared to age-matched wild-type mice, well before the onset of the 
development of severe AD pathology in this mouse model. These results suggest that 
microstructural changes in the corpus callosum may occur early during progression of 
AD (27,28,42,43). A trend of increasing T2 with age for Tg2576 mice was observed 
between 14 and 18 months of age, suggesting progressive decrease of the corpus 
callosum integrity. Microstructural changes in the corpus callosum have also been 
observed by DTI in Tg2576 mice (28,43) and PDAPP mice (44).  
 
In our study by means of T2 relaxation measurements, changes in the corpus callosum of 
Tg2576 mice were observed as early as 10 months of age, in line with a good sensitivity 
of T2 to microstructural changes. We focused on T2 measurements in the splenium, the 
posterior portion, of the corpus callosum of Tg2576 mice, since several AD studies have 
indicated that the posterior corpus callosum is affected more than the anterior part of the 
corpus callosum (45,46). In parallel, electron microscopy studies have revealed partial or 
complete demyelination in white matter regions near the Aβ plaques in an AD mouse 
model (PDAPP) (44). For another mouse model of AD (APP/PS1) however, very little 
change of the T2 was observed for the corpus callosum (31,32). In this study the region of 
interest for T2 measurements was placed close to the genu, the anterior part of the corpus 
callosum (31,32). It is thus likely that the ROI and corresponding differences in the 
expression levels of Aβ and the genetic background of the Tg2576 mice and APP/PS1 
mice affects the T2 results in the corpus callosum between both models.  
 
In addition to the corpus callosum, T2 changes were also investigated in gray matter 
regions. Our results confirm and extend previous studies (24,47), which showed a notable 
decrease in T2 for Aβ plaque rich regions such as the hippocampus and cortex in the old 
Tg2576 mice, compared to age-matched wild-type mice. Although the cause of the T2 
reduction in grey matter regions remains unclear, previous studies suggested that iron 
associated Aβ plaques may be involved in reducing the T2 in AD brain (24,47). In 
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contrast to Aβ-rich regions, T2 values did not show any significant change in the thalamus 
region between wild-type and Tg2576 mice at any age, which was associated with very 
low Aβ deposition in this region (47).  
 
3.5.2 Evaluation of microstructural changes in wild-type and Tg2576 mice with 
age  
A variety of interconnected pathological factors may contribute to changes in T2 values. 
For example myelin breakdown (48,49), axonal damage, gliosis (50) and vacuolation 
may increase T2 values and/or signal intensity in T2-weighted images (51), whereas iron 
and Aβ deposition decrease T2. To explore the potential molecular sources of the 
increased T2 relaxation time in the corpus callosum in our study, extensive histological 
analysis was performed. The histological data revealed severe abnormalities, such as 
marked demyelination, gliosis, vacuolation and Aβ deposition in the corpus callosum of 
the 18 months old Tg2576 mouse compared to age matched wild-type mouse. 
Interestingly, normal appearing white matter structure was observed in 11 month of age 
Tg2576 using myelin staining (data not shown). However a modest increase in activated 
astrocyte was visible in the corpus callosum of 11 months old Tg2576 mouse as 
compared to wild-type mouse (Fig. 3.2S). These results suggest that there might be some 
diffuse changes in normal appearing corpus callosum that activates the astrocytes, and 
these changes can be detected with quantitative T2 measurements. While an earlier study 
showed focal demyelination around Aβ plaques in gray matter and in the superficial 
subcortical white matter in Tg2576 mice (52), the demyelination in corpus callosum of 
Tg2576 mice has not been reported previously. The oligodendrocytes, which form myelin 
sheets, have been shown to be vulnerable to Aβ peptide (53), inflammatory agents, such 
as nitric oxide and reactive oxygen species (54-56). A recent study showed that when 
human derived Aβ plaques were injected into corpus callosum of rat brain, a variety of 
white matter abnormalities such as demyelination, decrease in oligodentrocyte number, 
and gliosis, occurred (57). Our results are consistent with previous in vivo (5) and 
postmortem studies in humans (12), showing that demyelination in the white matter 
regions is a marked morphologic component of AD.  
 
In addition, histological analyses revealed that activated glial cells are present in close 
proximity to Aβ deposits in the corpus callosum as well as the hippocampus and cortex 
regions supporting earlier findings where a strong association between Aβ and gliosis 
was observed (28,33,58-65). To observe how pathological changes in corpus callosum 
Chapter 3 
 88 
will further evolve at later age, histological analysis was performed in 29 months old 
Tg2576 mice. Comparison of histological data from 18 months and 29 months old 
Tg2576 mice show a clear increase in Aβ deposition, gliosis and demyelination with age.  
How activated astrocytes and microglia contribute to AD process remains unclear. When 
glial cells are activated, common inflammatory agents, such as the pro-inflammatory 
cytokines and reactive oxygen species, secreted from these cells can cause demyelination 
(66) and contribute to the disease progression. The damaged myelin, which is removed 
by activated microglia, can create microscopic fluid-filled spaces.  Eventually this can 
increase free to bound water ratio, and thus, may increase the T2 relaxation. However, the 
interpretation of T2 variation in AD due to activated microglia is complicated. For 
example, iron accumulated in microglial cells and Aβ deposits might decrease the T2 
relaxation time (67,68). When astrocytes, which play an important role in regulation of 
water homeostasis, are activated, they might cause enlargement of the extracellular space, 
which then becomes filled with more fluid (69), and thus increases the T2 values. 
Interestingly, abnormal functioning of a few astrocytic proteins such as aquaporin-4 
(AQP4), have been shown to play an important role in the occurrence of white matter 
microstructural changes including loss of axons and demyelination (70). However, the 
role of AQP4 and other astrocytic proteins in AD has not been fully revealed. A recent 
study reported a decrease in AQP4 expression in cultured mouse cortical astrocytes when 
these cell were subjected to high dose of Aβ42 (71). In another study, down regulation of 
aquaporin-1 gene expression is shown in AD (72). If AQP4 is down regulated due to Aβ 
deposits in the corpus callosum region, this might lead to a variety of abnormalities, such 
as reduced membrane water transport (73). Subsequently these abnormalities might lead 
to an increase in extracellular fluid and/or demyelination leading to an increase in the T2 
of the affected regions.  
 
The T2 values of the corpus callosum and gray matter regions of Tg2576 and control 
mice, acquired in this study, were not absolute (true) T2 values. The T2 depends on 
numerous factors, such as iron content of the tissue, free to bound water ratio and 
instrument parameters such as magnetic field strength and refocusing pulse interval (). 
Nevertheless, in preclinical and clinical studies, acquiring absolute T2 values of tissues is 
not the major concern, a good test-retest reliability of T2, and whether the value of 
diseased tissue is normal or not, is more important than absolute accuracy. In the present 
study good test-retest reliability was observed in the corpus callosum, thalamus, cortex 
and hippocampus regions of wild-type mice, showing that the T2 protocol used in this 
study is reliable with respect to the evaluation of disease progression.  
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To summarize, we have found promising results for the application of T2 measurements 
to track changes in the corpus callosum region of Tg2576 transgenic mice. Our results 
showed highly significant differences in the T2 values of the corpus callosum region of 
transgenic mice compared to the non-transgenic control group. The microstructural 
changes in the corpus callosum region were associated with demyelination and gliosis, 
which can lead to an increase in T2 values of the corpus callosum region. This suggests 
that T2 is a viable biomarker for the onset of symptoms of AD in this animal model. 
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Fig. 3.2S. Histological section (30 μm thick) of the brain of 11 months old wild type (A) and 
Tg2576 (B) mouse, stained with anti-GFAP antibodies. Note how reactive astrocytes are more 




Fig. 3.1S. Effect of refocusing interpulse interval () on T
2 
in cortex (CX) and corpus 
collasum (CC). T
2
 values were measured using MSME sequence with 4 different  values 
namely 6.6, 8.5, 10.5, and 18 ms. Values are expressed as mean T
2
 in ms ± standard 
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4 In vivo Measurement of Transverse Relaxation 
Times in the Mouse Brain at 17.6 T* 
4.1 Abstract 
The goal of this study is to establish the regional T1 and T2 values of the healthy mouse 
brain at ultra high magnetic field strength of 17.6 T and to follow regional brain T1 and T2 
changes with age. In vivo T1 and T2 values in several anatomical regions of the mouse 
brain: the hippocampus, cortex, thalamus, hypothalamus, corpus collosum, caudate 
putamen were measured. A field-dependent decrease in T2 is shown and validated with 
phantom measurements. T2 values at 17.6T typically increased with age in multiple brain 
regions except in the hypothalamus and the caudate-putamen, where a slight decrease 
was observed. Furthermore, T1 values in various brain regions of young and old mice are 
presented at 17.6T. A large gain in signal-to-noise ratio was observed at 17.6T. This 
study establishes for the first time the normative T1 and T2 values at 17.6T over different 
mouse brain regions with age. The estimates of in vivo T1 and T2 will be useful to 
optimize pulse sequences for optimal image contrast at 17.6T and will serve as baseline 
values against which disease related relaxation changes can be assessed in mice. 
4.2 Introduction 
Transverse and longitudinal relaxation times play an important role in optimizing MRI 
parameters such as contrast level or signal-to-noise ratio, and provide a quantitative 
indicator of tissue changes induced by various pathological conditions (1,2). The changes 
in T2 values of the brain tissue are widely used as a surrogate marker in the evaluation of 
various brain disorders (3,4). The in vivo T2 of brain tissue is related to the local water 
environment and the free-to-bound water ratio, which may change in response to cellular 
and axonal loss or membrane breakdown (5-8). For example, the process of breakdown 
of myelin in certain types of neurodegenerative disorders such as MS and AD, leads to 
alterations in the local water environment that increase the ratio of the free-to-bound 
water in tissue and thus increases T2 and T1 of white matter (5,9,10). The T2 and T1 also 
change in brain regions where brain iron is deposited in the form of ferritin and 
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hemosiderin (11). In addition both T1 and T2 values provide quantitative information 
about tissue changes in the healthy brain during aging (12,13). 
 
Mice are routinely used as models for studying human brain disorder. Due to the small 
size of the mouse brain, the present trend in in vivo mouse brain MRI is to move toward 
ultra-high magnetic field (≥ 7 T) for improved SNR, higher resolution, sensitivity and 
specificity (14-18). Thus, ultra-high magnetic field systems, such as 17.6 T, can serve as 
a powerful tool to detect more subtle abnormalities in anatomical and functional 
characteristics of emerging mouse models of neurodegenerative diseases (19). While the 
values for T2 relaxation time in different parts of the mouse brain have been published in 
different field strengths (2,12,20-23), there is no systematic assessment of the regional T2 
values for the healthy mouse brain at 17.6 T. The values of T1 relaxation time of various 
mouse brain regions have been reported at 17.6 T in young mice (18). However, age-
dependent changes in T1 have not been analyzed at this magnetic field strength. The 
C57BL/6J mouse is one of the most widely used inbred strains and the first to have its 
genome sequenced (24). It is generally used as a background strain for the generation of 
transgenic models of various brain diseases such as AD (19). In this study, we aimed to 
establish the values of regional T2 relaxation time for healthy C57BL/6J mouse brain in 
vivo at 17.6 T and to determine magnetic field dependent changes in T2. Phantom 
solutions were used to validate changes in T2 at different field strengths and to explore 
the validity of MSME sequence to measure T2. In addition we assessed age-related 
regional T2 and T1 changes in the mouse brain at 17.6 T. These estimates of in vivo T2 and 
T1 relaxation of the mouse brain will be useful to optimize MRI sequences for optimal 
image contrast and sensitivity in the mouse brain at 17.6 T. In addition, knowledge of 
age-related T2 and T1 changes in the healthy mouse brain is mandatory if disease-related 
deviations in T2 and T1 have to be studied in longitudinal studies. 
4.3 Materials and Methods 
4.3.1 Phantoms 
Phantom solutions containing different concentrations of Gadolinium-tetra-azacyclo-
dodecane-tetra-acetic acid (Gd-DOTA) (Dotarem; Guerbet Nederland BV, Gorinchem, 
the Netherlands) were prepared by diluting a stock solution of GD-DOTA (0.5 M) in 
phosphate buffer saline (pH=7.50). Dilution factors used for T2 measurements were 1/50 
(i.e., 10 mmol Gd-DOTA/L), 1/100, 1/200, 1/400, 1/800). The same phantoms were used 
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for both MRI and NMR experiments. For the SNR analysis, a phantom solution 
consisting of 20% H2O, 80% D2O, 1g/l CuSO4 was prepared.  
4.3.2 High-resolution NMR 
High-resolution NMR experiments were performed at 2.35 T, 9.4 T, and 17.6 T using a 
broadband 5-mm solution-state NMR probe. Radiation damping was minimized by using 
a restricted sample volume (capillary NMR tubes) in low-Q probes. The pulse sequence 
used for T2 measurements was based on the CPMG scheme. The pulse lengths of 90º and 
180º at all fields were 9.6 and 19.2 s, respectively. A variable list of 16 duration times 
between 90º and 180º pulse was adopted. Both the recycle delay and the longest duration 
time were kept at larger than 10 times of the expected T2 of each sample. 
4.3.3 Mice 
For all in vivo measurements female C57BL/6J mice were used. All of the animal 
experiments were approved by the institutional animal care and animal use committee of 
the University of Leiden in accordance with the NIH Guide for the Care and Use of 
Laboratory Animals. 
4.3.4 MRI 
All MRI measurements were performed using 400 MHz (9.4 T) and 750 MHz (17.6 T) 
vertical 89-mm bore magnets equipped with a 1 Tm
-1
 actively shielded imaging gradient 
insert (Bruker, Germany). A birdcage RF coil with an inner diameter of 2 cm was used 
for excitation and detection. The system was interfaced to a Linux PC running Topspin 
2.0 and ParaVision 5.0 software (Bruker Biospin GmbH, Germany). 
 
All in vivo MRI studies were conducted as previously described (25). Before imaging, the 
mice were initially anesthetized with 2% isoflurane (Forane, Abott, UK), in air (0.3 
l/min) and oxygen (0.3 l/min). During scanning the level of anesthetic was maintained 
between 1 and 1.5% to keep the breathing of the animal at a constant rate of ~50 breaths 
per minute. Animals were placed in the 20 mm birdcage RF coil with a special mouse 
head mask, which was used to administer the anaesthetic gas during the MR experiments. 
A respiration sensor, connected to a respiration unit, was placed on the abdomen to 
monitor the respiration rate. The respiration unit was connected to a computer running 
Bio-SAM respiration monitoring software (Bruker Biospin, Germany). During MRI 
imaging, the respiration rate of the mouse was constantly monitored and the body 
temperature of the mouse was kept constant by pumping warm water (30±1°C) through 
the gradient system. The rectal body temperature of the mouse during scanning was 
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measured to be 30±1°C. T2 measurements in phantom solutions were also conducted at 
30±1°C and were repeated at least 4 times.  
 
T2 values were measured with the MSME sequence that is based on the CPMG sequence, 
where transverse magnetization of a 90º pulse is refocused by a train of 180º pulses 
generating a series of echoes (26,27). The following imaging parameters were used for 
the phantom and in vivo experiments both at 9.4 T and 17.6 T: NA = 2; NS = 1 and/or 10 
with a slice thickness of 1.0 mm and an interslice thickness of 1.5 mm; Number of echoes 
= 16 with echo spacing = 8.5; A TR = 3 s with an effective spectral bandwidth = 50 kHz; 
FOV = 2.0 x 2.0 cm; Matrix size= 256 x 256; This yields an effective in-




. The total 
acquisition time for the experiment was 19 min 12 s. To study the dependence of T2 on 
the CPMG refocusing interpulse interval, the T2 measurements were performed using the 
MSME sequence with 16 echo and 4 different refocusing interpulse intervals, namely 5.6, 
8.5, 10, and 18 ms. The last 5 echo of 8.5 ms acquisition, the last 7 echo of 10 ms 
acquisition and the last 10 echo of 18 ms acquisition were discarded to provide 
comparable temporal sampling windows (namely, 5.6-91.04 ms, 8.5-93.50 ms, 10-90 ms, 
18-90 ms acquisitions, respectively). For the precise localization of ROIs on the brain 
regions for T2 measurements, a pilot scan of a mouse brain was acquired with multi-slice 
rapid acquisition using the RARE sequence (28) and subsequently ROIs were transferred 
to T2 maps to ensure precise regional placement. The following imaging parameters were 
used for the RARE sequence: TE = 11.67 ms (at 9.4 T) and 8.5 ms (at 17.6 T); TR = 
1500 ms (at 9.4 T) and 2000 ms (at 17.6 T); NA = 1, rare factor = 6; NS = 10, with slice 
thickness 1.0 mm; interslice thickness = 1.5 mm. To establish the test–retest reliability of 
T2 measurements, the same mice (n= 7) were scanned twice with an interval of 4 days 
and the phantom solution (10 mM) was scanned twice with an interval of six weeks. For 
the measurement of the SNR in the phantom solution, the mic-MSME sequence (Bruker, 
Paravision 5) was used. The following imaging parameters were applied both at 9.4 T and 
17.6 T: TE= 7 ms, RT = 1000 ms, NA = 1, FOV = 6.0 x 6.0, matrix = 256 x256, slice 
thickness = 1mm, NS = 11.  
 
T1 was measured with a multiple spin echo saturation recovery method with variable 
repetition time (RAREVTR). Slice excitation and refocusing were accomplished by 
hermite pulses, resulting in 90° and 180° pulse lengths of 1.4 and 0.9 ms, respectively. 
The following imaging parameters were used at 17.6 T: TE = 5.5 ms; TR-array = 0.1, 
0.18, 0.36, 0.6, 0.8, 1.0, 1.5, 2.0, 4.0, 6.0, 10.0 and 15.0 s; Matrix size= 128 x 128; FOV 
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= 1.7 x 1.7 cm; slice thickness = 0.9 mm. The total acquisition time for the experiment 
was 33 min 13 s. All images acquired single slices to prevent interslice modulation 
effects. The slice was positioned as described previously (18). To minimize the 
contribution of partial volume effects from cerebrospinal fluid, the ROIs were checked 
carefully on images collected with very thin slices (0.25 mm) using the same RAREVTR 
sequence with following parameters: RT = 6000 ms; TE = 17 ms; FOV = 1.5 x 1.5 cm; 
Matrix size = 256 x 256; NS = 10.  
 
For the comparison of the SNR for in vivo imaging at two different magnetic field 
strength (9.4 T and 17.6 T), the experiment was performed with the RAREVTR sequence 
using three different TR (6, 10 and 15 s) and TE (5.5, 16.5 and 27.5 ms). The following 
imaging parameters were used: NA = 1; TR-array = 15000, 10000, 6000; TE = 5.5, 16.5, 
27.4 ms; FOV = 1.7 x 1.7 cm; Matrix size= 128 x 128; slice thickness = 0.6 mm; 
Effective spectral bandwidth = 71428 kHz. The same mouse was used for SNR 
measurements at 9.4 T and 17.6 T. 
 
4.3.5 Data Processing 
 
4.3.5.1 Estimation of T2 and T1 
To calculate T2, ROIs were drawn on the images by using an image sequence analysis 
(ISA) tool package (Paravision 5, Bruker), which uses a fit function [y= A+C*exp (-
t/T2)], where A stands for the absolute bias, C is the signal intensity, and T2 represents the 
transverse relaxation time as defined earlier. The T1 values were determined by ISA using 
a fit function: M(t) = A + M0 * (1 - exp (t/T1), where M0 is the equilibrium magnetization.  
ROIs were manually defined for the hippocampus, cortex, thalamus, hypothalamus, 
corpus callosum, caudate-putamen, olfactory bulb and its glomerular layer  and muscle 
using the Allen Brain Atlas with the brain explorer program (http://mouse.brain-map.org) 
for referencing. For all animals, the T2 and T1 were the mean of the ROIs drawn on the 
right and left sides of the brain, except for the corpus callosum region. For phantoms, a 
cylinder was drawn on the inside of the axial figures of the tubes. The transverse 
relaxation rate (R2) was obtained from the equation: R2 = 1/T2 (s
-1
). Relaxivity of the 
contrast agent is defined as the efficiency by which an MRI contrast agent can accelerate 
the proton relaxation rate in a homogeneous medium (29). Relaxivity was calculated as 
the slope of the linear regression line of a plot of R2 vs concentration of MRI contrast 
agent (30).  
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4.3.5.2 Estimation of SNR 
The SNR in the images is measured as the average signal intensity over the ROI divided 
by the standard deviation of the noise.  
 
4.3.5.3 Statistics 
A paired and/or two-tailed student’s t-test was used to compare mean values. Statistical 
significance was assigned for values of P < 0.05. The reliability of the measurements was 
assessed by computing the ICC2,1 using a 2-way random effects ANOVA model and the 
absolute agreement definition (31,32). The associations between test-retest data were 
analyzed by the Pearson’s correlation coefficient (r) at a 0.05 significance level. An ICC 
close to 1 indicates excellent reliability. The Pearson’s r close to 1 indicates excellent 
association (31). 
4.4 Results  
4.4.1 Phantom studies 
Fig. 4.1a depicts the quantitative relaxivity of Gd-DOTA phantom solutions at 17.6 T 
using MRI and high-resolution NMR methods. The MSME and the single-slice multi-
echo MRI methods showed 11% and 8% lower r2 values, respectively, relative to the 
value acquired with the NMR method. Fig. 4.1b shows the r2 of Gd-DOTA phantom 
solutions determined at 2.35 T, 9.4 T, and 17.6 T using the high-resolution NMR method. 
As is clear from this figure, plots of the transverse relaxation rate, R2 (1/T2), vs. the Gd- 
DOTA concentrations (mM) reveal a linear dependence of the R2 on the concentration. In 
addition, the r2 values increased with increasing field strength. The value of r2 at 17.6 T is 
~18% and at 9.4 T ~11% higher relative to the value at 2.35 T. These results clearly show 
that T2 relaxation times of Gd-DOTA decrease with increasing field strength. To confirm 
that the 180°
 
pulses in the MSME sequence did not introduce spurious magnetization 
from stimulated echoes or from signals originating from outside the selected slices, T2 
decay curves from a Gd-DOTA phantom with echo spacings of 8.5, 13, 15, and 17 ms 
were acquired. An example of a T2 decay curve with an 8.5 echo spacing is depicted in 
Fig. 4.1S a (supplementary). The differences among T2 values acquired using the various 
echo spacings were statistically insignificant. In order to observe the variation of the T2 
between the 10 slices used in the multi-echo sequence, the T2 of the phantom (10 mM) 
was measured for each slice. No statistically significant variation in T2 values was 




the Gd-DOTA phantom, T2 data were acquired at 17.6 T using the MSME sequence at 
two different time points, separated by an interval of 46 days. The differences in mean T2 
values between two sessions were statistically insignificant, with P > 0.05. The intra-
class correlation coefficient and Pearson’s r values were measured as r = 0.92 and r = 
0.97, respectively, suggesting superior test-rest reliability (P < 0.05 in all cases) and 
minimum instrumental variations. The SNR performance at both magnetic field strengths 
was compared and was found to increase by a factor of 1.5 at 17.6 T as compared to 9.4 
T.  
 
4.4.2 In vivo studies 
Fig. 4.2a shows ROIs that were selected on a representative series of RARE images from 
a normal mouse to acquire T2. Fig. 4.2b depicts a graphical summary of the in vivo T2 
relaxation times for the mouse brain, at 9.4 T and at 17.6 T. A clear decrease in T2 values 
was observed in various brain regions at 17.6 T as compared to 9.4 T. However, the T2 in 
the muscle showed a relatively small decrease at 17.6 T as compared to 9.4 T. At both 
magnetic field strengths, the T2 were longest for the olfactory bulb and the grill regions, 
whereas the thalamus, the corpus callosum consistently show a shorter T2 compared to 
other brain regions. Table 4.1 depicts the quantitative summary of the in vivo T2 of the 
 
Fig. 4.1. (a) Scatter plots showing the changes in relaxation rates (R2) as a function of the Gd-DOTA 
concentration measured using MRI and NMR at 17.6 T; (b) Scatter plots showing the changes in R2 










 ± SE; MRI
m
, multi-slice multi-echo MRI; MRI
S
, single-slice multi-echo MRI. The 
correlation coefficient (Pearson’s r) of the linear fitting for all lines is 0.99. 
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mouse brain at 9.4 T and at 17.6 T. To validate the in vivo T2 dataset that was acquired 
using a multi-slice mode, the measurement was repeated in the single-slice mode. The T2 
values measured using the multi-slice mode were slightly higher than those from the 
single-slice mode (Fig. 4.2S); however, the systematic overestimation was less than 3 ms. 
The SNR for the cortex region of the mouse brain at both magnetic field strengths were 
compared and the SNR was found to increase by a factor of 1.6 at 17.6 T as compared to 
9.4 T. The dependence of cortex and corpus callosum T2 on the CPMG refocusing 
interpulse interval was investigated at 17.6 T (Fig. 4.3S). No statistically significant 
effect of the interpulse interval in the range of interest (between 5.6 and 18 ms) was 




Fig. 4.2. (a) MR coronal slices of a mouse brain, showing relevant ROIs, acquired with the RARE 
sequence at 17.6 T; (b) In vivo T2 relaxation times of different mouse brain regions acquired at 9.4 T 
and 17.6 T. The analyzed brain structures include the hippocampus (HC), cortex (CX), thalamus (TH), 
hypothalamus (HT), corpus callosum (CC), caudate-putamen (Cpu), olfactory bulb (OB), glomerular 
layer (GL) of OB; Muscle (M, internal reference). Values are expressed as mean T2 in ms ± SE (error 
bars). Two-tail student t test, P < 0.05 in all regions; n=5. 
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Table 4.2 shows test-retest reliability results of in vivo T2 measurements in multiple brain 
regions. The ICCs were statistically significant (P < 0.05) for all regions. The test-retest 
reliability was very good for cortex, thalamus, corpus callosum, caudate-putamen as well 
as muscle tissue, with the ICC ranging between 0.84 and 0.92. For hippocampus, and 
hypothalamus, ICC was 0.64 and 0.53, respectively. Table 2 also presents Pearson’s r, 
which showed superior association for all regions between two sessions. For all the brain 
regions Pearson’s r was statistically significant (P <0.05). However, Pearson’s r for HT 
regions was somewhat less than for the other regions (P = 0.062). The systematic error 
was checked by a paired t-test and results are  
shown in Table 4.2. 
 
Fig. 4.3 summarizes the age-related changes of the T2 for the mouse brain at 17.6 T. The 
in vivo T2 increases with age for multiple brain regions except for the hypothalamus and 
the caudate-putamen, where a slight decrease in T2 was observed. A significant increase 
in T2 was observed in the cortex region in 13.6 and 15.1 months old mice as compared to 
3.6 months old mice (Table 4.3).   
 
 
Fig. 4.3. Variation of in vivo T2 relaxation times of the mouse brain with age for the datasets 
measured in a magnetic field of 17.6 T. The analyzed brain structures include the hippocampus 
(HC), cortex (CX), thalamus (TH), hypothalamus (HT), corpus callosum (CC) and caudate-putamen 
(Cpu). Values are expressed as mean T2 in ms ± SE (error bars); n=5. Paired t test, *P < 0.05, 





Table 4.4 depicts the T1 values in multiple mouse brain regions in young (3 months old) 
and old (23 months old) mice at 17.6 T. Slightly shorter T1 in the corpus callosum and the 
caudate-putamen and slightly longer T1 in thalamus regions were observed in old mice as 
compared to young mice.  
4.5 Discussion 
4.5.1 Phantom studies 
The r2 acquired with the MSME sequence was in very close agreement with the values 
obtained using high-resolution NMR methods and the r2 derived from the data collected 
with the single-slice multi-echo sequence. The results validate the accuracy of the T2 
extracted from the data acquired with the MSME sequence at 17.6 T. In addition, 
phantom experiments showed that r2 decreases with increasing magnetic field strength. 
The apparent decrease of the T2 with increasing field strength is incompatible with 
straightforward BPP model dipolar relaxation processes that would lead to a T2 that is 
independent of the field strength (14,33). A decrease of the T2 with increasing field 
strength can be attributed to increasing microscopic susceptibility gradients, causing 
irreversible dephasing due to diffusion across those gradients (34-36). The MSME 
method used in this study to acquire T2 data is time-effective, since the sequence allows 
for imaging of several slices in a single scan (37,38).  
 
Previous studies, however, have reported that many factors, such as spurious echoes, can 
influence the ability to obtain accurate T2 data using the MSME method (37-42). 
Moreover, there are additional concerns regarding the effect of higher magnetic field 
strength including: magnetic field inhomogeneity, increased stimulated echo artifacts, 
and increased power deposition (43). We have demonstrated that spurious magnetization 
contribution from stimulated echoes in the 180
°
 pulses in the MSME sequence is 
negligible, since the estimated T2 values for the phantom did not change significantly for 
echo spacings of 8.5, 13, 15, and 17 ms. Also a spatially uniform T2 was observed 
throughout the 10 slices suggesting that the performance of the 180
°
 refocusing trains was 
spatially uniform for the MSME sequence (Fig. 4.1S b). In addition, excellent test-retest 
T2 reliability was measured by the MSME sequence. These results suggested very little 




A better SNR was observed for the phantom and the mouse brain at 17.6 T as compared 
to 9.4 T. If the relaxation parameters are ignored, the SNR is expected to increase linearly 
with magnetic field strength (14). The SNR has been reported to be proportional to 
magnetic field strength (B0) and the square root of (T2 /T1) in a fully relaxed pulse [SNR 
 B0 √T2/T1 ] (14). The lower-than-predicted increase in SNR at 17.6 T could be related 
with many factors such as changes in relaxation times (shorter T2 and longer T1), 
increased susceptibility effects, and larger field inhomogeneity (44,45). All these factors 
can limit the SNR increment at higher fields. In addition, it has been reported that 
experimental conditions such as RF coils, pulse sequences and preamplifiers also affect 
the SNR quantification (46).  
 
4.5.2 In vivo studies 
In this study, the in vivo T2 for several regions of the healthy mouse brain have been 
presented at 17.6 T. While the T2 in different parts of the transgenic and non-transgenic 
mouse brain have been published for different field strengths (2,12,20-23), and T2 maps 
of the ischemic mouse brain were provided at 17.6 T, a systematic assessment of the T2 
for the healthy mouse at 17.6 T was not yet obtained. Our results at 17.6 T are well in line 
with data from healthy rat brain acquired at 16.4 T (47). In addition, the in vivo T2 of the 
mouse brain determined at 9.4 T in this study reproduces well with earlier published data 
(2,12,20,22). In particular, the T2 values of the corpus callosum, hippocampus and  
 
Table 4.3: In Vivo T2 Values of the Mouse Brain with Age at 17.6 T
a
 
       Age (Month)   
Structure 3.6 13.6 15.1 
HC 27.84 ± 0.10 28.06 ± 0.24 28.60 ± 0.38 
CX 27.70 ± 0.16  28.20 ± 0.15* 28.38 ± 0.10* 
TH 25.83 ± 0.08 26.03 ± 0.26 26.06 ± 0.28 
HT 26.64 ± 0.41 26.15 ± 0.23 26.28 ± 0.23 
CC 25.73 ± 0.08 26.17 ± 0,48 26.28 ± 0.53 
Cpu 26.96 ± 0.13 26.42 ± 0.29 26.55 ± 0.27 
M 21.25 ± 0.44 21.53 ± 0.31 21.23 ± 0.16 
 
a
Values are expressed as mean relaxation times (ms ± SE), kn = 5. HC = 
Hippocampus, CX = Cortex, TH = Thalamus, HT = Hypothalamus, CC 
= Corpus callosum, Cpu= Caudate-putamen, M = Muscle. Paired two-
tailed t-test,*
 




caudate-putamen are in excellent agreement with earlier reports at 9.4 T (20). Our results 
also illustrate for various brain regions that the T2 decreases with increasing magnetic 
field strength. While this is consistent with earlier reports (14,36,43,48,49), the extent of 
T2 reduction was found to depend on the composition of the tissue. The T2 of the muscle 
tissue did not show a strong field dependence, which could be attributed to a lower 
intracellular molecular mobility of the water in the muscle tissue than for the brain tissue. 
The decrease of tissue T2 with increasing magnetic field strength has been explained in 
terms of the molecular processes of diffusion and/or chemical exchange of spins between 
regions with different magnetic field strengths (34,36,50,51). Magnetic field 
inhomogeneities increase linearly with increasing magnetic field strength, and are created 
by local susceptibility gradients, which can be microscopic (e.g., surrounding blood 
vessels) as well as macroscopic (e.g., around the sinuses and petrous bone) (34). 
Diffusion across these magnetic field gradients dephases the transverse magnetization of 
the water protons, resulting in an overall decrease of the T2. The magnitude of these 
gradients increases with field strength and therefore their effect on T2 increases with the 
magnetic field strength (14). This process is referred to as dynamic dephasing and it 
depends, among other things, on the refocusing interpulse interval , defined as half the 
interval between successive 180° pulses in a CPMG sequence (36,52). It has been shown, 
in theory and experiments, that T2 decreases with increasing  (36,52-54). Several works 
have investigated the effect of varying  on T2 measurements in biological tissues 
(51,52,54-56). In our experiments, in order to obtain an estimate of the effect that the 
refocusing interpulse interval has on T2, we repeated the T2 measurements with 4 
different  values, between 5.6 ms to 18 ms (supplementary Fig. 4.3S). No statistically 
significant dependence of the T2 on the interpulse interval was observed. This result 
suggests that the changes observed in T2 values with age depend more on changes in 
tissue properties in the individual brain structures rather than magnetic field disturbances. 
In our study, a relatively short refocusing interpulse interval (8.5 ms) was used. However 
even in these conditions, contribution of diffusion and/or chemical exchange on T2 is 
inevitable. In practice, most studies are performed with  values no shorter than those 
used here, and thus for optimization of contrast and general clinical applications, the T2 
values represented here are expected to be valid and reproducible under similar 
experimental conditions across platforms. In our study, age-dependent changes in T2 in 
multiple brain regions, including the cortex, hippocampus, thalamus and corpus callosum, 
was observed at 17.6 T (Fig. 4.3; Table 3.3). In particular, for the cortex the T2 relaxation 




recently published age-dependent T2 measurement in human brain at 3 T (13). T2 values 
of the brain tissue can increase with age in response to cellular and axonal loss or 
membrane breakdown (5,57,58). These aging processes reduce the number of 
macromolecules and increase free water content. This raises the ratio of free-to-bound 
water protons and as a result contributes to the increase in T2 values (13). The lower T2 
values in the younger mice as compared to the older mice might also be caused by the 
increased susceptibility effects at 17.6 T. The higher susceptibility effects in the younger 
mice due to a very high ratio of air space to brain tissue may reduce T2 values, especially 
at higher fields (17.6T). Nevertheless, T2, acquired in this study using a short interpulse 
interval  = 8.5 ms, is in the plateau region and seems to be less sensitive to magnetic 
disturbances induced by local magnetic susceptibility effects. This would also indicate 
that the changes observed in T2 values with age in our study depend on tissue cellularity 
changes, rather than magnetic disturbances. A few mouse brain regions, such as the 
hypothalamus and the caudate-putamen, show a slight decrease in T2 values with age, 
which could result from increased deposition of paramagnetic substances such as ferritin 
and hemosiderin (11,59). In human, basal ganglia e.g. caudate-putamen structures show 
increased levels of paramagnetic substances with age (13). Falangola et al. (22) did not 
observe any age-dependency of T2 in normal mouse brain at 7 T. The differences in the 
findings can be explained by the ROI definition, use of different imaging parameters, 
susceptibility effects and the field strength. Specially, the ROI employed in our study 
covers only the somatosensory and the retrosplenial granular cortex regions. However in 




Tissue Young Old 
HC 2.14 ± 0.04 2.16 ± 0.03 
CX 2.02 ± 0.05 2.07 ± 0.04 
TH 2.05 ± 0.06   2.17 ± 0.08* 
CC 1.99 ± 0.05   1.92 ± 0.05* 
Cpu 2.01 ± 0.03   1.96 ± 0.04* 
OB 1.97 ± 0.03 1.96 ± 0.04 
M 2.39 ± 0.07 2.37 ± 0.03 
a
Mean T1 relaxation times of young (3 months) and old (23 
months) mice (s ± SD), n=5. HC = Hippocampus, CX = 
Cortex, TH = Thalamus, CC = Corpus callosum, Cpu= 
Caudate-putamen, OB = Olfactory Bulb, M = Muscle. 
Two-tailed t-test: *P < 0.05 compared to young mice. 
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the study of Falangola et al., the ROI covers a bigger volume, i.e., the ectorhinal, 
perirhinal, piriform, somatosensory and retrosplenial granular cortex regions.  
  
It is known that technical challenges such as increased RF field inhomogeneity, increased 
RF power deposition and susceptibility effects are prevalent at higher fields (15), which 
can give rise to errors in the T2 measurements (39,40). However, our results show that 
these factors have negligible effect on the test-retest reliability and accuracy of the 
phantom and in vivo experiments.  While the MSME sequence provides considerable 
time savings compared to a single-slice multi-echo sequence, cross-talk between slices 
can occur (60). However this cross-talk can be substantially decreased by adding slice 
gaps between adjacent slices (61). In our study, an inter-slice gap of 150% of the slice 
thickness was used that substantially reduced the influence of cross-talk between slices 
(61). In addition, it has been reported that introducing gaps between neighboring slices 
also helps in reducing magnetization transfer effects by increasing the resonance offset 
(60). A slight overestimation of the in vivo T2 was observed with the MSME sequence 
compared to the single-slice sequence at 17.6 T. However, the T2 of the mouse brain 
observed with the MSME sequence were consistently within 3 ms of the values acquired 
with the single-slice sequence for all regions (supplementary Fig. 3.2S).  
 
In clinical evaluations T2 values are often inaccurate in absolute terms due to the 
systematic errors related to e.g. the type of curve fitting used in the analysis, and the echo 
train length. In clinical evaluations, however, a good test-retest reliability of T2, and 
shorter scan times are more important than absolute accuracy. The observation that the 
increase in T2 using the MSME sequence as compared to the single-slice multi-echo 
sequence is relatively small, the absence of obvious inter-slice variation of T2 in multi-
slice imaging, and good test-retest reliability indicated that the MSME protocol can serve 
to find optimal parameters for T2 weighted sequences at 17.6 T. In addition, the MSME 
sequence can be safely used for evaluation of disease progression in the mouse models of 
neurodegenerative diseases at 17.6 T. 
 
In addition to T2 values, we also measured in vivo T1 changes for a variety of brain 
regions in young (3 months of age) and old (23 months of age) mice at 17.6 T. The T1 
values obtained for young mice are in excellent agreement with an earlier report at 17.6 T 
(18). Comparison of the T1 values in multiple brain regions reveals a slightly lower T1 for 
the corpus callosum and the caudate-putamen regions in old mice as compared to young 
mice. These age-dependent T1 changes are in agreement with measurements in humans 
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(at 1.5 T) and rats (at 16.4 T) (47,62-64). In addition, we also observed slightly longer T1 
in the thalamus region of old mice as compared to young mice. An increase in the 
thalamus T1 values with age has also been reported in MRI scans collected from humans 
at 1.5 T (64,65). The age-related changes in T1 might reflect various physiological 
processes. For example an increase in iron content of brain tissue can lead to a decrease 
in T1, while a decline in the number of myelinated fibers can cause an increase in T1 
(10,11).  
 
In conclusion, our results provide a comprehensive and quantitative in vivo T2 profile for 
various mouse brain regions at 17.6 T and show that the T2 decreases substantially at 17.6 
T compared to 9.4 T. In addition, age-related T2 and T1 changes in the mouse brain were 
observed, which provides a useful reference for comparison with disease-related 
deviations in T2 and T1 relaxation for future studies.  
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Fig. 4.2S. In vivo T2 relaxation times of different mouse brain regions acquired by single-slice and 
multislice methods at 17.6 T. Error bars represent the SE over four animals. HC = hippocampus , CX = 
cortex, TH =  thalamus, HT =  hypothalamus, CC = corpus callosum. The T2 values measured using 
multi-slice mode were slightly higher than those from the single-slice mode; however, the systematic 




Fig. 4.1S. (a) Plot showing signal intensity versus echo time (TE) for Gd-DOTA phantom (10mM) 
solution measured using the MSME sequence with 16 echo times (TE); (b) T2 (ms ± SE) of Gd-DOTA 
phantom (10mM) solution measured using the MSME sequence with 10 slices. No statistically 























Fig. 4.3S. Effect of refocusing interpulse interval  on the T2 in cortex (CX) and corpus 
collasum (CC). T2 values were measured using the MSME sequence with 4 different  
values, namely 5.6, 8.5, 10, and 18 ms. Values are expressed as mean T2 in ms ± SD 
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*Parts of this chapter were published in Curr Med Imag Rev 2011; 7:1:80-87 
5 General Discussion and Future Outlook* 
In this thesis the potential applications of high-resolution MR angiography and 
relaxometry to study Alzheimer’s disease pathology in transgenic mouse models were 
investigated at ultra high magnetic fields. The specific focus was both on the MRA and 
the relaxometry method optimization, as well as their application to monitor AD related 
changes, such as blood flow abnormalities and myelin breakdown, and to understand the 
underlying mechanisms of these changes.  
5.1 Monitoring blood flow abnormalities in an AD mouse model  
In Chapter 2 it was shown that improved visualization of cerebral vasculature of mouse 
brain is possible by applying in vivo MRA at 17.6 T. The results presented in this chapter 
show that MRA image quality at 17.6 T is already significantly higher than the one 
acquired at 9.4 T. Due to ultra-high field strength (17.6 T) and use of strong gradients, the 
small sized arteries were very clearly imaged up to the level of the pial vessels.  
 
The optimized MRA method was applied to detect AD related blood flow defects in 
cerebral arteries in Tg2576 mice at 17.6 T. In addition, amyloid plaque load was assessed 
based on T2 weighted images and also in subsequent immunohistochemical staining of 
histological sections.Abnormal hypointensities seen on the MRA scans were counted and 
scored for comparison with wild-type mice. Signal hypointensities and plaque load were 
both shown to increase with age in the affected mice and to differ from wild-type mice. 
Overall decrease in the brightness of the arteries was observed in transgenic mice as 
compared to wild-type. In particular, the middle cerebral artery and the anterior 
communicating artery were the most significantly affected vessels in Tg2576 mice. 
Histological data revealed that CAA might be responsible for impaired cerebral blood 
flow, thereby contributing to the progression of AD. Our data suggest that after a certain 
level of elevation of Aβ deposits, blood flow abnormalities can be observed with MRA, 
thus challenging the view that elevated soluble Aβ levels provide sufficient and necessary 
condition to cause severe blood flow abnormalities.  
 
Along with CAA, many other factors such as oxidative stress and Aβ induced endothelial 
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dysfunction might have contributed to blood flow abnormalities. It has been reported that 
cerebrovascular dysfunction in aged Tg2576 mice could be fully rescued by antioxidants 
and the peroxisome proliferator-activated receptor agonist pioglitazone without reducing 
brain Aβ plaque load (1).  
 
Rescuing cerebrovascular function in AD can be an interesting alternative to counteract 
AD pathology (1). Imaging blood flow and vasculature architecture changes during AD 
progression with MRA could be used to evaluate success of potential therapies targeting 
blood flow abnormalities. The ability of ultra high field MRA to provide information 
about small cerebral vessels at high spatial resolution has the potential to improve our 
understanding about the AD. The MRA technique discussed here still needs further 
development to be used diagnostically or as a tool for drug discovery. MRA sensitivity 
can be increased by use of higher magnetic field strengths, a cryogenic RF probe and 
non-toxic contrast agents (2).  
5.2 Probing white matter abnormalities in AD using T2 measurements  
Neuropathological diagnosis of AD is still based on the presence of primarily gray matter 
alterations due to abundant Aβ deposition in these regions. In recent years, a strong 
interest in white matter pathology seen in AD has developed (3-5). In particular 
abnormalities in corpus callosum (i.e. largest white matter structure in the brain), has 
been associated with AD pathology. Since the corpus callosum plays an important role in 
functional connectivity and cognitive processing, abnormalities in corpus callosum 
integrity can lead to clear functional defects, including impairment in cognitive processes 
(6). A systematic assessment of the T2 values in the corpus callosum in mouse models of 
AD is still missing.  
 
In Chapter 3 T2 changes in the corpus callosum in a mouse model of AD with age (10 to 
18 months) were monitored. A significant elongation in T2 values of the corpus callosum 
in Tg2576 mice compared to wild-type was observed at all ages (10-18 months), whereas 
a significant decrease in T2 was observed in the cortex and hippocampus of 18 months 
Tg2576 mice. Myelinated fibers in corpus callosum are composed of lipids, proteins and 
water. Demyelination and gliosis increase free-to bound ratio of the water in the tissue, 
which causes an increase in T2 values. In this chapter the increase in T2 values in corpus 
callosum was correlated with demyelination and gliosis, which were confirmed with 
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histology. The decrease in the T2 values observed in the hippocampus and cortex can be 
due to magnetic field inhomogeneities created by iron containing Aβ plaques.  
 
This chapter highlights open questions and motivates future research. First, there are no 
longitudinal T2 studies that were conducted to assess changes in white matter integrity in 
the corpus callosum in mouse models of AD. Second, future studies are required to 
determine how vascular factors affect the white matter integrity of the corpus callosum. 
Third, the behavioural outcome of white matter abnormalities remains unclear. There is 
clearly a need for studies correlating these abnormalities with classic hallmarks of AD 
pathology, such as amyloid load, gliosis and neurofibrillary tangle. Hybrid MRI/PET 
devices might be employed for this purpose. Interestingly, in this chapter white matter 
integrity changes in corpus callosum did not show a strong correlation with Aβ load.  
 
White matter consists of myelinated fiber tracts that interconnect various parts of the 
cerebral hemisphere. Abnormalities in integrity of white matter may cause disconnection 
between different regions of the brain. This raises the hypothesis that AD includes a 
disconnection disorder. Future studies using novel MRI methods, such as resting state 
functional MRI, can investigate networking problems related with white matter 
abnormalities. Our results suggest that a decrease in white matter integrity in the corpus 
callosum might be an early event in the course of AD and raises the possibility that both 
gliosis and myelin related pathology might be contributing to AD onset.  
 
Currently, there exist little data concerning the neurobiological basis of white matter 
integrity decline in AD. A better understanding of the neurobiological underpinnings of 
microstructural changes in corpus callosum and other white matter regions associated 
with AD-risk has the potential to aid the development of novel pharmacological 
intervention strategies for AD. New treatment strategies, intended to protect axon and 
myelin integrity in seniors at risk of AD, might be more successful to prevent or slow 
down the disease progression. 
5.3 In vivo Measurement of T2 in the Mouse Brain at 17.6 T 
Previous studies have shown that many factors influence the ability to obtain accurate 
multi-component T2 data in vivo using CPMG imaging sequences, including: the SNR, 
the refocusing interpulse interval and partial volume effects (7-9). Further improvement 
in the accuracy of T2 data can be achieved using a variety of strategies, such as using an 
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optimized refocusing interpulse interval and increased magnetic field strength. In 
particular, ultra-high magnetic field systems provide greater SNR and increased 
resolution, which can increase the sensitivity and specificity of T2 measurements to detect 
subtle tissue changes during AD progression.  
 
In Chapter 4, the normative T2 and T1 values at 17.6 T over different mouse brain regions 
with age were established. In this chapter, the dependence of tissue T2 values on magnetic 
field was also investigated by comparing the T2 values acquired at 17.6 T with those 
acquired at 9.4 T. Field dependent decrease in tissue T2 values was observed with 
increasing field strength. The T2 dependence on magnetic field strength is in 
contradiction to the Bloembergen-Purcell-Pound dipolar relaxation model, which predicts 
T2 to be independent of the field strength (10,11). The decrease in tissue T2 with 
increasing field strength observed in this study can be explained by increased 
microscopic susceptibility effects, causing irreversible dephasing due to diffusion (12).  
 
In this chapter, T2 changes of brain regions were monitored with age at 17.6 T. A 
relatively short refocusing interpulse interval was used to acquire T2 values of mouse 
brain regions in order to decrease the contribution of diffusion or chemical exchange 
effects on T2 data. Many brain regions showed an age-dependent increase in T2 values. 
The age-dependent increase in tissue T2 values can be due to neuronal and axonal tissue 
degradation (13-16), whereas the decrease in tissue T2 values could result from deposition 
of paramagnetic substances such as ferritin and hemosiderin (17,18). Overall these results 
show that age-dependent changes in tissue T2 relaxation times can be accurately 
measured at 17.6 T. These estimates of in vivo T2 relaxation of mouse brain will be useful 
to optimize sequences for optimal image contrast and will serve as a useful reference for 
comparison with disease related deviations in T2 and T1 values.  
 
5.3.1 Future outlook 
 
5.3.1.1 Metabolic profiling of AD by magnetic resonance spectroscopy 
The new updated criteria and guidelines for the diagnosis of AD defines three stages of 
AD, which includes preclinical (19), mild cognitive impairment (20) and dementia (21). 
These updated guidelines aim to accelerate the development and implementation of 
potential biomarkers of AD to identify predementia and even preclinical asymptomatic 
stages of the disease. In vivo neuroimaging methods have the capability to detect early 
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structural, functional and metabolic changes in AD brain. While structural and functional 
changes can be detected with MRI, MRS can provide a wealth of information on various 
aspects of in vivo neurochemistry, including neuronal health, gliosis, osmoregulation, 
energy metabolism, neuronal-glial cycling, and molecular synthesis rates in brain of AD 
patients (22-25). In mouse models of AD, the relation between metabolic changes that 
can be detected in vivo using MRS and cerebral Aβ accumulation is examined by 
sacrificing mice of different ages. However, the correlation between Aβ deposition and 
neurochemical changes would be more reliable if both could be measured in vivo in the 
same mice repeatedly over time.  
In vivo detection of Aβ plaques using MRI without using a contrast agent has been 
reported in transgenic mouse models of AD (26,27). Subsequently our group has 
performed the first longitudinal µMRI study to follow the development of plaques with 
age in the same mice (28). In a follow-up study we studied the temporal relationship 
between the severity of plaque deposition monitored by in vivo µMRI and the altered 
neurochemical profile monitored by in vivo MRS in the same Tg2576 mice with age 
between 12 and 18 months (Fig. 5.1) (29). A clear increase in the level of taurine was 
observed with age between 14 and 18 months (Fig. 5.1). The increase in taurine was more 
drastic between 16 and 18 months and was correlated with the severity of plaque load at 
these ages. A decline in NAA with age was clearly observed between 12 and 18 months 
(Fig. 5.1). However, the drastic decrease in NAA was registered at the age between 14 
and 16 months. In addition, the analysis of the plaque load and its temporal relationship 
with each altered metabolite are underway.  
In recent years, the use of in vivo MRS in AD research has become more widespread. 
Common findings of in vivo MRS in human AD patients and AD mouse models are: a 
decrease in NAA and an increase in mIns. Because of these consistent findings, these 
metabolic changes have been proposed as potential biomarkers for early diagnosis of AD. 
These changes also correlated with an increase in amyloid plaque load and a decrease in 
cognitive performance. Although a decrease in NAA and an increase in either mIns or 
taurine have been consistently observed in AD, these changes are not specific only for 
AD. The same changes have been shown to occur in other neurodegenerative diseases 
such as Huntington’s disease, Parkinson’s disease and in other brain disorders (30-33). 
Therefore, specific in vivo MRS markers of AD are still missing. The use of localized in 
vivo 
1
H MRS in mice is often hampered by low sensitivity of local measurements due to 






Fig. 5.1. Correlation between the development of Aβ plaques monitored by in vivo µMRI and changes 
in neurochemical profile monitored by MRS with age in the brain of the same AD transgenic mouse at 
the age of 12 months (A), 14 months (B), 16 months (C), and 18 months (D). 
1
H-MR spectra were 
obtained from a 8 µl voxel placed in the cortex-hippocampus region at 9.4T using a PRESS sequence 
(TR/TE 3500/15 ms). A decrease in NAA and an increase in Tau with age can be clearly seen in the 
MR spectra on the left. MR images were acquired at 9.4T using a RARE sequence (TR/TE 6s/10.5ms; 
RARE factor 4). The magnified subsampled areas of the MR images on the right show an increase in 





which result in limited signal-to-noise ratio. A significant limitation of 1D 
1
H MRS is the 
spectral crowding since most of the metabolite resonances are restricted to a narrow 
chemical shift range of 5 ppm. Detection of most of the metabolites is hampered by 
spectral overlap with other metabolites. Therefore important neurotransmitters and other 
metabolites, which are in low concentration or with multiple splitting, cannot be reliably 
resolved (34,35). This limitation makes the data difficult to interpret, particularly in 
relation to metabolites such as GABA, Glu and Gln.   Thus, further improvement in in 
vivo 
1
H MRS is required to monitor small but crucial changes in the AD mouse brain.  
Future MRS studies in AD mice should take advantage of the availability of higher 
magnetic field strengths, new experimental MRS methods and of the option to exploit 








Na. In vivo MRS studies in AD mice have been 
performed in magnetic field strengths up to 9.4T. For nuclear MRS a higher magnetic 
field strength is always desirable. Moving from 9.4T to higher fields, such as 17.6T, is 
expected to be beneficial, since high field strength will improve signal-to-noise ratio as 
well as spectral resolution, thus enabling the reliable identification of metabolites at low 
concentrations or with coupled spin systems. The problem of spectral overlap can be 
reduced by using 2D MRS methods. Compared to conventional, one-dimensional MRS, 
localized 2D MRS reduces the problem of spectral overlap considerably, as the 
resonances are dispersed over a two-dimensional surface, allowing the separation and 
unambiguous assignment of resonances of several metabolites in a single measurement. 
Recently several 2D MRS sequences have been used for studying brain metabolism in 
human subjects, although not in AD patients, using clinical MRI scanners (35-37). The 
techniques based on localized variations of the 2D chemical shift correlated spectroscopic 
sequence appear most promising with regard to identifying metabolites that cannot be 
resolved using conventional 1D MRS sequences due to spectral crowding. Our group has 
recently implemented a localized 2D MRS technique at 9.4T and, for the first time, 
obtained highly resolved localized 2D MR spectra from the living mouse brain (34). Use 
of localized 2D MRS allowed clear and simultaneous detection of a large number of brain 
metabolites based on their network of cross-peaks in localized regions of the mouse brain 
in vivo. A clear separation of the cross-peaks of Glu, Gln, GSH and GABA, allowed 
direct in vivo assignment of resonances of these coupled spin systems. In addition, the 
cross- peak of NAAG was separated from NAA (34). The 2D spectrum also showed 
well-resolved cross-peaks of many other metabolites present at low concentration, such 
as alanine, aspartate, α-glucose, tyrosine, threonine, and glycerol. These results 
demonstrate the feasibility of 2D MRS to get localized access to the mouse brain for 
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efficient identification of metabolites (34). This method can be applied to mouse models 
of AD and has a great potential for resolving brain metabolites hidden under overlapping 
multiplets, which will have significant implication in detecting new biomarkers of AD in 
the near future.  
Other spectroscopic imaging techniques, such as chemical shift imaging, proton echo 
planar spectroscopic imaging and double echo-filter metabolite imaging can also be 
applied to mouse models of AD (38). In addition to 
1
H MRS, the use of other nuclei can 
be exploited in AD, although other nuclei are not as sensitive as 
1
H. The sensitivity levels 
of other nuclei relative to 
1






F), and 27.2% (
7
Li) 
(39). Despite its low sensitivity, 
31
P is one of the most commonly used nuclei in brain 
research after 
1
H MRS, which provides important information about changes in the levels 
of membrane phospholipids and high energy metabolites (40). Another nucleus, 
13
C, has 
also been used in humans but it has not yet been applied in mouse models of AD. Despite 
its low sensitivity, 
13
C MRS can help to overcome significant problems of spectral 
overcrowding and magnet frequency. For example it can provide invaluable data, 
particularly in relation to Glu-Gln cycling and astrocytic activity (41,42). Recent 
applications of 
13
C MRS in humans have shown that it may have potential application in 
AD as well as other neurodegenerative disorders (41). This method can even be of greater 





In conclusion, in vivo MRS is a powerful tool to unravel the neurochemical basis of AD 
in transgenic mouse models. The full potential of MRS in AD mouse model has not yet 
been exploited, and we expect that higher magnetic field strengths combined with 
exploitation of other nuclei than 
1
H will further and substantially increase our 
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Dementia due to AD has had tremendous impact on the affected individuals, care givers 
and medical health care system. Both developed and developing countries will face the 
challenge of coping with a high frequency of AD, which is a characteristic of aging 
societies. However, there is still no effective treatment for AD and the underlying 
mechanisms of the disease remain largely unknown.   
 
While aging remains one of the most significant risk factors for development of AD, 
increasing evidence strongly points to the potential roles of cerebrovascular and white 
matter abnormalities in AD development. A better understanding of the manner in which 
these abnormalities contribute to disease progression can be achieved by in vivo 
characterization of AD related pathologies. To this end, MR based techniques such as 
magnetic resonance angiography and relaxometry serve as effective non-invasive tools to 
longitudinally monitor changes in AD brain. The resolution and sensitivity of these MR 
based techniques used in clinical studies, however, are hampered by low magnetic fields 
(≤3T). To overcome this limitation, MRI systems having high field strength (≥7T) have 
been developed. Ultra high magnetic field MRI provides high sensitivity, increased 
resolution and better spectral dispersion of brain metabolites. These systems may cause a 
paradigm shift in AD research through the in vivo observation of subtle structural, 
metabolic and functional changes in the AD brain. 
 
An advanced understanding of AD pathology can be achieved by validating in vivo 
changes with histology. To this end, transgenic mouse models of AD, which develop 
amyloid pathology, serve as valuable preclinical models to study the disease. In vivo 
imaging of these mouse models at ultra high magnetic field strengths can permit a better 
understanding of the underlying cellular mechanism of AD. This knowledge can be used 
to develop potential biomarkers and promising treatment strategies to impede and/or 






In this thesis, a variety of MR based techniques were optimized and employed to 
longitudinally monitor the AD progression in transgenic mouse models of the disease at 
9.4 T and 17.6 T. The relevance of this work is summarized in Chapter 1.   
 
In Chapter 2, age-dependent blood flow alterations were examined in a Tg2576 mouse 
model of Alzheimer's disease using MR angiography at 17.6 T. AD is linked to 
abnormalities in the vascular system. Here ultra-high field MRA was employed to 
monitor age-dependent cerebrovascular alterations in the Tg2576 model. The blood flow 
alterations observed in the middle cerebral artery and anterior communicating artery 
increased in the Tg2576 mice compared to the wild-type mice over time. Histological 
data revealed that these alterations such as signal voids might be correlated with severity 
of Aβ type of CAA. These results show that ultra-high field MRA is a valuable tool to 
monitor blood flow alterations longitudinally in living mice.  
 
In Chapter 3, in vivo T2 changes were longitudinally monitored in the corpus callosum, 
the largest white matter structure in the brain, of the Tg2576 mice. Being sensitive 
marker for tissue pathology, in vivo T2 changes depicted severe pathology in the corpus 
callosum as well as in the gray matter regions of Tg2576 mice. In particular, a marked 
increase in T2 values was observed in the 10 months of age Tg2576 mice suggesting early 
microstructural changes in the white matter. These pathologies were correlated with 
gliosis, demyelination, and Aβ deposition.  
 
In Chapter 4, age-dependent regional brain T1 and T2 changes in C57BL/6J mice were 
established at 17.6T. Being the main component of contrast in MRI, the estimates of in 
vivo T1 and T2 will be useful in future studies to optimize pulse sequences for optimal 
image contrast at 17.6T and will serve as baseline values against which disease related 
relaxation changes could be assessed in mice. Chapter 5 presents general discussion and 





Dementie ten gevolge van AD heeft grote gevolgen voor de personen die er aan lijden, 
zorgverleners, en het zorgstelsel. Ontwikkelde landen en ontwikkelingslanden zullen de 
uitdaging aan moeten gaan met veelvuldig voorkomende AD, wat karakteristiek is voor 
vergrijzende maatschappijen. Er is nog geen effectieve behandeling voor AD en de 
onderliggende werking van deze ziekte blijft voor het grootste deel onbekend. 
 
Hoewel veroudering een van de belangrijkste risicofactoren is voor ontwikkeling van 
AD, is er steeds meer bewijsmateriaal dat wijst op de potentiële rol van 
cerebrovasculaire- en witte massa-afwijkingen in de ontwikkeling van AD. Een beter 
begrip van de manier waarop deze afwijkingen bijdragen aan de ziekeprogressie kan 
worden verkregen met in vivo kenschetsing van AD gerelateerde ziektes. Om dit te 
bewerkstellingen dienen MR gebaseerde technieken zoals magnetische resonantie 
angiografie en relaxometrie als effectieve non-invasieve instrumenten om de 
veranderingen in de AD hersenen longitudinaal te volgen. De resolutie en gevoeligheid 
van deze MR gebaseerde technieken die gebruikt worden in klinische studies worden 
daarentegen belemmerd door zwakker magnetische velden (≤3T). Om deze beperking te 
overwinnen zijn er MRI systemen met sterke magnetische velden (≥7T) ontwikkeld. MRI 
met zeer sterke magnetische velden biedt grote gevoeligheid, hogere resolutie en betere 
spectrale dispersie van hersenmetabolieten. Deze systemen zullen mogelijk een 
paradigmaverschuiving in AD onderzoek veroorzaken door in vivo waarneming van 
subtiele structurele, metabolische en functionele veranderingen in de AD hersenen. 
 
Een vergaand begrip van AD afwijkingen kan bereikt worden door de in vivo 
veranderingen te vergelijken met histologie. Hiertoe dienen transgene muismodellen van 
AD, die een amyloidafwijking ontwikkelen, tot waardevolle preklinische modellen om de 
ziekte te bestuderen. Het in vivo afbeelden van deze muismodellen bij zeer hoge 
magnetische veldsterkte staat een beter begrip van de onderliggende cellulaire 
mechanismen van AD toe. Deze kennis kan gebruikt worden om potentiële biomarkers en 
veelbelovende behandelingsstrategieën te ontwikkelen om de AD ontwikkeling te 
belemmeren en/of te voorkomen. 
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In dit proefschrift zijn verschillende MR gebaseerde technieken geoptimaliseerd en 
gebruikt om de ontwikkeling van AD in een transgeen muismodel van de ziekte te 
onderzoeken bij 9.4T en 17.6T. De toepasselijkheid van dit werk is samengevat in 
Hoofdstuk 1. 
 
In Hoofdstuk 2 zijn leeftijdsafhankelijke bloedstroomveranderingen onderzocht in het 
Tg2576 muismodel van Alzheimer met MR angiografie bij 17.6T. AD is gekoppeld aan 
afwijkingen in het vasculaire systeem. Hierbij werd zeer hoge magnetische veldsterkte 
MRA gebruikt om de leeftijdsafhankelijke cerebrovasculaire veranderingen in Tg2576 te 
volgen. De bloedstroomveranderingen opgemerkt in de middelste hersenslagader en de 
arteria communicans anterior nemen in de loop der tijd toe in de Tg2576 muizen ten 
opzichte van de wild-type muizen. Histologische gegevens hebben onthuld dat deze 
veranderingen zoals signaalleegtes wellicht gecorreleerd zijn met de hevigheid van het 
Aβ type van CAA. Deze resultaten tonen aan dat zeer hoge magnetische veldsterkte 
MRA een waardevol instrument zijn om de bloedstroomveranderingen longitudinaal te 
onderzoeken in levende muizen. 
 
In Hoofdstuk 3 zijn in vivo T2 veranderingen longitudinaal onderzocht in het corpus 
callosum, de grootste witte-massastsructuur in de hersenen, van de Tg2576 muizen. In 
vivo T2 veranderingen zijn gevoelige indicatoren voor weefselpathologie en laten grote 
pathologische verstoringen in het corpus callosum en in de grijze-massagebieden van de 
Tg2576-muizen zien. In het bijzonder werd een opvallende verhoging in T2 waarden 
gemeten in de 10 maanden oude Tg2576-muizen, wat vroege microstructurele 
veranderingen in de witte massa suggereert. Deze afwijkingen werden gecorreleeerd met 
gliosis, demyelinisatie, en Aβ-afzetting. 
 
In Hoofdstuk 4 werden leeftijdsafhankelijke T1 en T2 veranderingen in de hersengebieden 
van C57BL/6J-muizen vastgelegd bij 17.6T voor de grootste contrastcomponent van de 
MRI. De schattingen van in vivo T1 en T2 zullen nuttig zijn in toekomstig onderzoek om 
de pulsreeksen te optimaliseren voor optimaal afbeeldingscontrast bij 17.6T, en zullen 
dienen als ijkingswaarden waartegen ziektegerelateerde relaxatieveranderingen kunnen 
worden geëvalueerd in muizen. Hoofdstuk 5 presenteert een algemene discussie en 
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